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Punitee Garyali 
LAFORA DISEASE: MECHANISMS INVOLVED IN PATHOGENESIS 
 
Lafora disease is a neurodegenerative disorder caused by mutations in 
either the EPM2A or the EPM2B gene that encode a glycogen phosphatase, 
laforin and an E3 ubiquitin ligase, malin, respectively. A hallmark of the disease 
is accumulation of insoluble, poorly branched, hyperphosphorylated glycogen in 
brain, muscle and heart. The laforin-malin complex has been proposed to play a 
role in the regulation of glycogen metabolism and protein degradation/quality 
control. We evaluated three arms of protein quality control (the autophago-
lysosomal pathway, the ubiquitin-proteasomal pathway, and ER stress response) 
in embryonic fibroblasts from Epm2a-/-, Epm2b-/- and Epm2a-/- Epm2b-/- mice. 
There was an mTOR-dependent impairment in autophagy, decreased 
proteasomal activity but an uncompromised ER stress response in the knockout 
cells. These defects may be secondary to the glycogen overaccumulation. The 
absence of malin, but not laforin, decreased the level of LAMP1, a marker of 
lysosomes, suggesting a malin function independent of laforin, possibly in 
lysosomal biogenesis and/or lysosomal glycogen disposal. To understand the 
physiological role of malin, an unbiased diGly proteomics approach was 
developed to search for malin substrates. Ubiquitin forms an isopeptide bond 
with lysine of the protein upon ubiquitination. Proteolysis by trypsin cleaves the 
C-terminal Arg-Gly-Gly residues in ubiquitin and yields a diGly remnant on the 
peptides. These diGly peptides were immunoaffinity purified using anti-diGly 
antibody and then analyzed by mass spectrometry. The mouse skeletal muscle 
	   vii 
ubiquitylome was studied using diGly proteomics and we identified 244 non-
redundant ubiquitination sites in 142 proteins. An approach for differential 
dimethyl labeling of proteins with diGly immunoaffinity purification was also 
developed. diGly peptides from skeletal muscle of wild type and Epm2b-/- mice 
were immunoaffinity purified followed by differential dimethyl labeling and 
analyzed by mass spectrometry. About 70 proteins were identified that were 
present in the wild type and absent in the Epm2b-/- muscle tissue. The initial 
results identified 14 proteins as potential malin substrates, which would need 
validation in future studies. 
Peter J. Roach, Ph.D., Chair 
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INTRODUCTION 
1. Glycogen Structure 
Glycogen is a branched polymer of glucose that serves as a means to 
store glucose in times of nutritional plenty for utilization in times of need. In 
mammals, the large majority of glycogen is found in skeletal muscle and liver but 
other tissues such as kidney, heart, adipose tissue and brain are also capable of 
synthesizing glycogen (1). Polymerization of glycogen occurs via α-1,4-glycosidic 
linkages between glucose residues. Branch points are introduced via α-1,6-
glycosidic linkages at the C6 hydroxyl of a glucose residue in the chain (Figure 
1). The glycogen structure has inner B-chains, which would normally contain two 
branch points, and outer A-chains, which are unbranched (Figure 2). A full-size 
glycogen molecule consists of 12 tiers with about 55000 glucose residues, a 
molecular mass of ~107 kDa and a diameter of ~44nm (2,3). The frequency of the 
branch point, about 1 every ~12 residues, determines the structure, topology and 
solubility of glycogen. Glycogen molecules cannot be detected by light 
microscopy but can be visualized under the electron microscope. They have 
been described as rosette-like β-particles in muscle and larger α-particles in liver 
(4), the latter being aggregations of the former. 
Glycogen predominantly contains glucose residues but it also contains 
traces of glucosamine (5,6) and phosphate (7). Of the two, the covalent 
phosphate has been most studied. In the 1980s, phosphate was reported to be 
an integral part of glycogen (7). Recent work has shown the frequency of 
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Figure 1. Glycosidic Linkages in Glycogen. Polymerization 
occurs at α-1,4 glycosidic linkages and branching occurs are α-1,6 
glycosidic linkages. The numerical nomenclature of the carbons is 
represented in one of the glucose molecules. 
 
Figure 2. Glycogen Structure. A tiered model for glycogen 
organization in which the outer A-chains are unbranched and the 
inner B-chains carry an average of two branches. The black circle 
represents glycogenin. 
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glycogen phosphorylation as one phosphate for ~650 glucoses in rabbit skeletal 
muscle and one per ~2000 residues in mouse muscle glycogen (8,9). 
Furthermore, mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
analyses have shown that the phosphate exists as C2-, C3 and C6- 
phosphomonoesters (10,11). A mechanism for the introduction of C2-phosphate 
via a side reaction of the normal synthetic enzyme glycogen synthase has been 
proposed (12). The origin of the other phosphates is less clear at this time. The 
physiological role, if any, of phosphate is not known; however excessive 
phosphorylation of glycogen is associated with a neurodegenerative disorder, 
Lafora disease (see section 5). Phosphate is also present as C3- and C6-
phosphomonoesters in plant amylopectin, a complex carbohydrate similar in 
structure to mammalian glycogen (13). Introduction of phosphate into 
amylopectin is mediated by dikinase enzymes (14) and is thought to play a 
critical role in disrupting the semi-crystalline structure of the polymer during its 
degradation (15). Besides phosphate, there are also trace amounts of 
glucosamine in rabbit liver glycogen, but not in the skeletal muscle and heart 
glycogen (5). The role of glucosamine in glycogen is not well understood, 
although it is thought that glucosamine can be incorporated into glycogen by 
glycogen synthase using UDP-glucosamine as the glucosyl donor (5). 
A glycogen molecule undergoes multiple cycles of expansion and 
contraction, potentially accumulating chemical and metabolic insults in each 
cycle. This results in an aberrant structure that sometimes escapes normal 
metabolism leading to formation of an insoluble material similar to other insoluble 
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deposits in various neurological diseases. In normal aging tissues, even in the 
absence of disease glycogen-like deposits are observed such as corpora 
amylacea in brain (16) and cardiac colloid in heart (17), which supports the idea 
that these chemical modifications in glycogen may reflect the age of the molecule 
and its need for disposal (18). 
There are several proteins associated with glycogen (19-23) and glycogen 
along with the proteins and elements of the sarcoplasmic reticulum have been 
termed ‘glycogen particles’ (24,25) (Figure 3). The glycogen associating proteins 
bind to glycogen, sometimes to each other and to membranes. The known 
glycogen-associated protein include glycogenin, the initiator of glycogen 
synthesis, the metabolic enzymes glycogen synthase, glycogen phosphorylase, 
debranching enzyme AGL and regulatory proteins such as phosphorylase kinase 
and members of the protein phosphatase 1G family (26). The β-subunit of AMP-
activated protein kinase (AMPK) has been shown to bind to glycogen (27,28) via 
its carbohydrate-binding module 20 domain (CBM20) (29,30). Recently, laforin 
(31,32) and starch-binding domain protein 1 (Stbd1) or genethonin (33,34) have 
been identified as glycogen-binding proteins via a CBM20 domain. The 
branching enzyme interacts with glycogen but it does not form a stable 
association (34). All glycogen-associating proteins have been shown to play a 
functional role in the metabolism of glycogen. 
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Figure 3. Glycogen Particles. Glycogen-associated proteins: the 
metabolic enzymes glycogenin (GN), glycogen synthase (GS), 
phosphorylase (Ph) and debranching enzyme (DBE); the 
phosphatases type 1 catalytic subunit (PP1c) and laforin; the 
protein kinases phosphorylase kinase and AMPK; the PP1 
glycogen-targeting subunits RGL, GL and PTG; the membrance-
anchoring protein Stbd1. Stbd1, RGL and phosphorylase kinase 
anchor to membranes. 
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2. Glycogen Metabolism 
Glycogen synthesis, glycogenesis, and breakdown, glycogenolysis, are 
both highly regulated processes. The precursors for glycogen synthesis are 
either glucose, derived from newly ingested carbohydrate, or gluconeogenic 
precursors, such as alanine or lactate in an indirect glyconeogenesis pathway 
(35). Glycogenesis (Figure 4) is triggered with the entry of glucose in the cell by 
one or more of the several glucose transporters (GLUTs) (36). The enzyme 
glucokinase/hexokinase converts glucose to glucose-6-phosphate (G6P). G6P is 
then converted to glucose-1-phosphate (G1P) by phosphoglucomutase (PGM) 
that is required for the formation of uridine diphosphoglucose (UDPG) by UDPG 
pyrophosphorylase (UGP). Glycogen synthesis is initiated by the specialized self-
glycosylating protein glycogenin (37-39), a member of the family 8 retaining 
glycosyltransferases (GT8). Glycogenin forms a short glucose polymer by self-
glycosylation reactions using UDPG as substrate. Glycogenin can interact 
directly with glycogen synthase via its C-terminus. Glycogen synthase (GS) then 
catalyzes the bulk formation of the glycogen molecule by adding new glucose 
residues via α-1,4-glycosidic linkages. The glycogen branching enzyme (GBE) 
introduces the branchpoints via α-1,6-glycosidic linkages every ~12 glucose 
residues. GBE cleaves an α-1,4-glycosidic linkage, excises a segment of the 
existing oligosaccharide and reforms an α-1,6-glycosidic linkage. The rate-
limiting step in glycogenesis is the reaction catalyzed by glycogen synthase. 
The initiation of glycogenolysis (Figure 4) occurs by the rate-limiting 
enzyme glycogen phosphorylase (GPh). GPh belongs to the family of retaining 
	   7 
glycosyltransferases (GT35). It catalyzes the phosphorolytic breakdown of the α-
1,4-glycosidic linkages of glycogen to produce glucose-1-phosphate and 
glycogen(n-1) (1). GPh activity requires pyridoxal phosphate (PLP) as a cofactor 
involved in the acid/base catalysis by phosphorylase. GPh stalls four glucose 
residues from an α-1,6-glycosidic linkage necessitating the action of another 
enzyme, the glycogen debranching enzyme (AGL). There are two catalytic 
activities in two separate domains associated with AGL. The N-terminal domain 
has α-amylase-like activity which hydrolyzes an α-1,4-glycosidic linkage to leave 
a single branched residue in an α-1,6-glycosidic linkage and reforms an α-1,4-
glycosidic linkage between the detached glucose residues and the main chain. 
The C-terminus of AGL contains a domain with amylo-1,6-glucosidase activity 
that removes the remaining branched glucose residue. 
Glycogen metabolism is controlled hormonally via covalent modification 
and allosteric ligand binding of key enzymes involved in glycogen synthesis and 
degradation (Figure 5). Glycogen synthase is regulated by covalent 
phosphorylation of 9 or more sites at the N- and C-termini (1). Phosphorylation 
inactivates GS and dephosphorylation activates the enzyme. Glycogen synthase 
kinase-3 (GSK-3) phosphorylates four important regulatory sites of GS, thus 
inhibiting its activity (1). Type-1 protein phosphatase (PP1) associates with one 
of several glycogen-binding targeting subunits including RGL (GM) and PTG and 
mediates dephosphorylation of GS. Phosphorylation and allosteric ligand binding 
also regulate glycogen phosphorylase, which is activated by phosphorylation and 
inactivated by dephosphorylation. Phosphorylase kinase phosphorylates and 
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activates GPh and PP1 catalyzes the dephosphorylation and inactivation of GPh 
(Figure 5). 
In mammals, the postprandial rise in blood glucose triggers the secretion 
of insulin from β-cells of the pancreas into the bloodstream. Insulin binds to the 
insulin receptor of the peripheral tissues and triggers the uptake of glucose, 
raising the levels of intracellular glucose-6-phosphate, which activates glycogen 
synthase. Insulin receptor consists of two α- and two β-subunits. Binding of 
insulin to the extracellular domain of the α-subunit causes a conformational 
change that triggers activation of the β-subunit tyrosine kinase resulting in 
transphosphorylation of tyrosine residues in the β-subunit. The activated kinase 
then phosphorylates the insulin receptor substrates. The phosphorylated 
tyrosines in these substrates recruit signaling molecules containing SH2 
domains. Recruitment of the p85 subunits of phosphatidylinositol-3-kinase (PI3K) 
leads to its activation. PI3K phosphorylates the membrane lipid 
phosphatidylinositol-4-5-bisphosphate (PIP2) converting it to phosphatidylinositol-
3,4,5-triphosphate (PIP3). PIP3 further binds and activates the protein kinase 
PDK1, which phosphorylates and activates protein kinase B PKB/AKT at catalytic 
T308 (40). AKT, in turn, phosphorylates an N-terminal serine of GSK3 to inhibit 
its ability to phosphorylate and inactivate GS (41). Insulin signaling thus regulates 
the activity of GS by preventing its phosphorylation through inactivation of GSK3 
(Figure 5). In contrast to insulin, glycogenolysis is promoted by epinephrine and 
glucagon in muscle and liver, respectively. A signaling cascade is initiated 
activating adenyl cyclase that catalyzes the conversion of ATP to cAMP. cAMP 
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activates PKA that phosphorylates phoshorylase kinase which in turn 
phosphorylates and activates glycogen phosphorylase (Figure 5). 
 
 
Figure 4. Glycogen Metabolism Overview. GLUT, glucose 
transporter; HK, hexokinase; G6Pase, glucose-6-phosphatase; 
PGM, phosphoglucomutase; AGL, debranching enzyme; GPh, 
glycogen phosphorylase; UGPPase, UDP-glucose 
pyrophosphatase; GN, glycogenin; GS, glycogen synthase; BE, 
branching enzyme. 
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Figure 5. Regulation of Glycogen Metabolism. Schematic 
representation of major signaling pathways regulating glycogen 
metabolism. GSK3, glycogen synthase kinase 3; PIP2, 
phosphatidylinositol-4-5-bisphosphate; PIP3, phosphatidylinositol-
3,4,5-triphosphate; PI3K, phosphotidyl inositol kinase; PP1, protein 
phosphatase 1. 
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3. Lysosomal Disposal of Glycogen 
Glycogen is mainly broken down in the cytosol by glycogen phosphorylase 
and debranching enzymes. However, some glycogen is also transported to the 
lysosomes, where it is directly hydrolyzed to glucose by the action of lysosomal 
α-glucosidase (acid maltase, GAA) (Figure 4) (42). This is probably not the major 
degradation pathway, but defects in the enzyme GAA lead to accumulation of 
glycogen in lysosomes, causing a glycogen storage disorder, Pompe disease 
(OMIM 232300) (43) (see section 4.3). The exact mechanism by which glycogen 
is transferred to the lysosomes in unknown, but it is most likely to involve 
autophagy-like vesicular trafficking. Autophagy is a mechanism for recycling of 
cellular materials under conditions of nutritional deprivation or stress (44,45). 
Macroautophagy (hereafter called autophagy) is the most studied type and it 
involves engulfment of cargo within a double membrane to form 
autophagosomes that fuse with the lysosome where the cargo is ultimately 
degraded (46). A number of autophagy-related proteins (ATGs) are involved in 
the process of forming autophagosomes and eventually their fusion with 
lysosomes to form autophago-lysosomes (47) (Figure 6). There are variants of 
the basic autophagic process that have separate controls, specific cargo and 
different functions (48,49). ‘Glycogen autophagy’ has been described in the 
literature in livers of newborns (50). There is a prenatal accumulation of glycogen 
in several organs of the fetus, such as liver and heart, mainly to provide energy 
reserves for use during the immediate postnatal period (51), when 
gluconeogenesis is not well developed. Another connection of glycogen with 
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autophagy is provided by Pompe disease (52). The Gaa-/- mice show massive 
accumulation of glycogen in lysosomes, an increase in the glycogen containing 
autophagosomes and late endosomes, referred to as ‘autophagic build up’ (52). 
Raben et al. also generated mice that combined a homozygous null GAA 
mutation with muscle-specific disruption of the genes encoding autophagy-
related proteins, Atg5 (53) or Atg7 (54). In both of these mice, there was a 
decrease in the autophagic build up in the muscle, but loss of autophagy 
worsened the clinical phenotype. 
In Saccharomyces cerevisiae at the onset of nutrient deprivation, glycogen 
is accumulated as a carbon and energy reserve. The SNF1 gene is essential for 
regulation of gene expression by glucose repression and yeast mutated in SNF1 
has diminished glycogen accumulation and concomitant inactivation of glycogen 
synthase. Analysis of an unbiased genetic screen for yeast glycogen metabolism 
showed that two yeast autophagy genes, ATG1 and ATG13 could restore the 
defective glycogen storage of snf1 mutant strain (55). A genome-wide survey in 
yeast for genes affecting glycogen metabolism revealed ~60 genes involved in 
vesicular trafficking or vacuolar function, including genes encoding 13 of 17 
proteins involved in structure or assembly of the vacuolar ATPase (56). These 
studies provide further evidence suggestive of vesicular transport of glycogen to 
the lysosome for degradation but the exact mechanism is not known. It is 
expected that glycogen would associate with membranes if it were to be involved 
in vesicular transport. There have been a few reports that show, using electron 
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microscopy, glycogen particles to be close to membranes, endoplasmic reticulum 
in liver (57) or sarcoplasmic reticulum in muscle (20). 
Figure 6. Autophagy. Schematic representation of the process of 
autophagy. Engulfment of the cargo within a double membrane 
leads to formation of autophagosomes that fuse with the lysosomes 
to form autophagolysosomes where the cargo is ultimately 
degraded. Microtubule associated protein 1 light chain 3 (LC3-I) is 
incorporated into the autophagosomes and is lipidated to LC3-II. 
Upon formation of the autophagolysosomes, LC3-II is recycled 
back to the cytosol. 
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In a proteomics study, starch-binding domain protein 1, Stbd1, was 
identified as a glycogen-associated protein and it was speculated to be involved 
in anchoring glycogen to membranes in different cell compartments (23). Stbd1 
was first localized, as the novel human gene GENX-3414, at chromosome 4q24-
q25 (58). It was proposed that the encoded protein is associated with T-tubules 
and sarcoplasmic reticulum (58). Janecek et al. identified the same protein in a 
bioinformatics study and referred to it as genethonin (59). Recent studies by 
Jiang et al. have shown that Stbd1 may anchor glycogen to membranes (33,60). 
Stbd1 has a C-terminal CBM20 domain (58) and a highly conserved N-terminal 
24-residue hydrophobic sequence (Figure 7). Stbd1 binds to polysaccharides, 
preferentially with less branched structures such as amylopectin or glycogen 
isolated from mouse models of Lafora disease (33). In mice lacking glycogen, 
glycogen synthase knockout mice, Gys1-/-, Stbd1 levels are dramatically 
decreased, indicating a connection between glycogen metabolism and Stbd1 
(33). Yeast two-hybrid studies with Stbd1 as bait identified two members of the 
mammalian ATG8 family of autophagic proteins; GABARAP (γ-aminobutyric acid 
type A receptor-associated protein) and GABARAPL1 (GABARAP-like 1) (33,60). 
	  	  
Figure 7. Starch-binding Domain Protein 1. Schematic 
representation of Stbd1 showing the N-terminal hydrophobic 
domain, the leucine zipper and the C-terminal carbohydrate-binding 
domain (CBD). 
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Co-immunoprecipitation assays confirmed the interaction of Stbd1 with 
GABARAPL1 (60). It was proposed that Stbd1 anchors glycogen to membranes 
and participates in lysosomal trafficking of glycogen, glycophagy with the help of 
GABARAPL1. Since Stbd1 preferentially binds to less branched glycogen, it is 
possible that Stbd1 plays a role in disposal of aberrant glycogen as part of quality 
control. 
 
4. Glycogen Storage Diseases 
Glycogen storage diseases (GSD) or glycogenoses are caused by inborn 
errors of metabolism involving either glycogen synthesis or degradation of the 
polysaccharide. As a result, glycogen is altered in quantity and/or quality. 
 
4.1. Glycogen Storage Disease Type 0 
GSD 0 is an autosomal recessive form of fasting hypoglycemia of infancy, 
caused by mutations in the GYS2 gene, the liver isoform of glycogen synthase, 
resulting in an almost complete loss of liver glycogen. The patients have fasting 
hypoglycemia, high blood ketones, low levels of alanine and lactate and 
postprandial hyperglycemia, hyperlactatemia and hyperlipidemia (61). 
 
4.2. Glycogen Storage Disease Type I: von Gierke’s disease 
It is the most common of all the glycogen storage diseases and is caused 
by mutations in the G6PC (glucose-6-phosphatase) and G6PT (glucose-6P 
translocase) genes that are required for delivery of hepatic glucose to the blood 
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stream. There is an accumulation of glycogen and fat in liver and kidneys and the 
patients suffer from hypoglycemic seizures, hepatomegaly, renomegaly, growth 
retardation and lactic acidosis (62,63). 
 
4.3. Glycogen Storage Disease Type II: Pompe’s disease 
Pompe’s disease is an autosomal recessive disorder caused by deficiency 
of lysosomal acid α-glucosidase enzyme resulting in an accumulation of glycogen 
in the lysosomes of heart and skeletal muscle as mentioned previously. Patients 
have mutations in GAA gene and present with cardiomegaly, cardiomyopathy, 
hypotonia, muscle weakness, failure to thrive and depending on the severity of 
the mutation death can ensue within the first year (43,64). Targeted disruption of 
the Gaa gene in mice reproduces the critical features of Pompe’s disease, 
although the symptoms are milder and develop later relative to the onset of the 
human disease and the mice do not die (65). Studies on double Gaa-/- Gys1-/- 
mice showed a marked reduction in the heart and muscle glycogen levels, 
reduced lysosomal swelling and autophagic buildup and a complete reversal of 
cardiomegaly (66).  
 
4.4. Glycogen Storage Disease Type III: Cori’s disease 
Cori’s disease is an infantile autosomal recessive disorder caused by 
mutations in the AGL gene resulting in a deficiency of glycogen debranching 
enzyme (67). The disease is characterized by accumulation of glycogen in liver, 
muscles and heart presenting as infanitle hypoglycemia and failure to thrive (67). 
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4.5. Glycogen Storage Disease Type IV: Andersen’s disease 
Andersen’s disease is the most severe form of glycogen storage disease 
with defects in the GBE1 gene encoding the branching enzyme (68). Patients 
present with symptoms of hepatospleenomegaly, failure to thrive and cirrhosis of 
liver (69). The accumulated glycogen has long stretches of unbranched glucose 
chains resulting in a loss of solubility, leading to cellular dysfunction. Patients 
usually die within 5 years of disease onset because of liver failure. 
 
4.6. Glycogen Storage Disease Type V: McArdle disease 
McArdle disease is caused by deficiency of muscle phosphorylase 
because of mutations in the PYGM gene. Patients present in young adulthood 
with exercise intolerance, painful muscle cramps and early fatigue (70). 
 
4.7. Glycogen Storage Disease Type VI: Hers’ disease 
Hers’ disease is caused by deficiency of the liver phosphorylase due of 
mutations in the PYGL gene. Patients present with hypoglycemia, 
hyperlipidemia, hyperketosis, hepatomegaly and growth retardation (71). 
 
4.8. Glycogen Storage Disease Type VII: Tarui’s disease 
Tarui’s disease is caused by mutations in the PFKM gene, which encodes 
the muscle phosphofructokinase. The mutation causes impairment in the ability 
of phosphofructokinase to phosphorylate fructose-6P to fructose-1,6-
bisphosphate. There is a build up of glycolytic intermediates, which are thought 
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to drive excessive glycogen synthesis mediated by elevation of allosteric 
activation of glycogen synthase by glucose-6-P. The patient presents with 
exercise-induced muscle cramps, myoglobinuria and hyperuricemia (72). 
 
5. Lafora Disease 
5.1. Preamble 
Lafora progressive myoclonus epilepsy or Lafora disease (LD; OMIM 
254780) is a fatal autosomal recessive neurodegenerative disorder. The onset of 
the disease is usually in the second decade of life with stimuli-sensitive grand 
mal tonic clonic, absence, visual and myoclonic seizures which progresses to 
dementia, psychosis, cerebellar ataxia, dysarthria, mutism, amaurosis and 
muscle wasting (73-77). Death occurs usually within 10 years of the onset 
because of respiratory failure. LD is diagnosed in patients by biopsy of sweat 
glands in the armpit that confirms the presence of pathognomonic Lafora bodies 
(Figure 8). Lafora bodies are composed of poorly branched, insoluble glycogen-
like polymers that are periodic acid-Schiff-positive (PAS+). Lafora bodies are 
most commonly found in organs with the highest rates of glucose metabolism, 
including brain, skeletal muscle, heart and liver (73,78). LD is mostly found in 
parts of the world where the rate of consanguinity is high. This includes isolated 
ethnic populations in the Mediterranean basin of Spain, France, Italy, southern 
USA and Quebec, Canada, and in few regions of Central Asia, the Indian 
subcontinent, Africa and Middle East. There is no preventive or curative 
treatment available for LD yet (79).  
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Figure 8. Lafora Body. An electron micrograph showing a layered 
polyglucosan Lafora body with dense center inside an unidentified 
cell process (80). 
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5.2. Clinical Homogeneity and Locus Heterogeneity in Lafora Disease 
More than 95% of the cases of LD have mutation in either of the two 
genes Epilepsy progressive myoclonus 2A (EPM2A) and Epilepsy progressive 
myoclonus 2B (EPM2B or NHLRC1) (32,81,82). The remaining cases could 
result from mutations in the promoter or enhancer regions of the two known 
genes or from mutations in a third, as yet unidentified locus (83). To date more 
than 100 mutations have been reported to be associated with LD (The Lafora 
Progressive Myoclonus Epilepsy Mutation and Polymorphism Database, 
http://projects.tcag.ca/lafora/). In a meta-analysis about 100 distinct mutations 
were discovered in over 200 independent LD families (84). About half of the 
mutations were missense mutations and one-quarter were deletions. The 
analysis revealed that EPM2A mutations are more common in Spain and LD 
patients in Italy and France have predominantly EPM2B mutations. In the Indian 
subcontinent and Central Asia, the mutations are distributed evenly (84). 
Clinically, the symptoms in LD patients with mutations in either of the genes are 
indistinguishable. However, studies have shown that the course of disease was 
longer in EPM2B mutation patients who had a slower progression and slightly 
milder symptoms in comparison to patients with EPM2A mutation (85-88). 
 
5.3. EPM2A gene 
EPM2A, a 130 kb four-exon gene, was localized on chromosome 6q24 by 
linkage analysis and homozygosity mapping (89). LD patients are either 
homozygous or compound heterozygous for loss-of-function mutations (32). 
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EPM2A encodes a 331-residue dual-specificity phosphatase, laforin (82), which 
contains an N-terminal carbohydrate-binding domain (CBD) (residues 1-124) that 
can bind complex carbohydrates such as glycogen, amylopectin and 
polyglucosan (90,91). Laforin also has a C-terminal dual-specificity phosphatase 
domain (DSPD) (residues 157-326) with the signature motif HCXXGXXRS/T 
(Figure 9) and in vitro experiments have shown that laforin can dephosphorylate 
phospho-serine/threonine, phospho-tyrosine and p-nitrophenyl phosphate 
(pNPP) (92). Laforin is ubiquitous, with the highest expression in skeletal muscle, 
liver, kidney, heart and brain (93). 
To date 64 different mutations have been described in the EMP2A gene 
(The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism 
Database, http://projects.tcag.ca/lafora/). All the mutations are evenly distributed 
across the four exons of the gene affecting either the polysaccharide binding 
and/or the dual specificity phosphatase activity of laforin except one mutation that 
has no effect on polysaccharide binding or phosphatase activities but affects 
interaction with PTG (94). Despite remarkable allelic heterogeneity in EPM2A, 
there is a high prevalence of one mutation, R241X, in the Spanish population 
(40%), most likely due to a founder effect and recurrent events (95,96). Both 
functional CBD and DSPD are required for laforin function since loss-of-function 
mutations of either domain causes disease symptoms (84). 
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Figure 9. Laforin and Malin. Schematic representation of A) 
Laforin showing the four exons, the N-terminal carbohydrate 
binding domain (CBD) and the C-terminal dual-specificity 
phosphatase domain (DSPD). R241X is the most common mutation 
found in EPM2A in Lafora patients. B) Malin showing the exon, the 
N-terminal RING finger domain and the six NHL motifs. P69A, 
G158fs and C26S are the most frequent mutations in Lafora 
patients with EPM2B mutations. 
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5.4. EPM2B gene 
Chan et al. (81) identified the second gene implicated in LD, EPM2B or 
NHLRC1, which is a single exon gene localized on chromosome 6p22 (97). 
EPM2B codes for a 395-residue protein malin, a putative E3 ubiquitin ligase with 
an N-terminal RING finger domain, common to all E3 ubiquitin ligases (98,99), 
followed by six NHL motifs, thought to be involved in protein-protein interactions 
(100) (Figure 9). 
To date 61 different mutations have been described in the EPM2B gene 
(The Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism 
Database, http://projects.tcag.ca/lafora/). All the mutations are evenly distributed 
across the gene. The missense mutation P69A, affecting the RING finger 
domain, is the most frequent mutation observed in EPM2B followed by the 
G158fs mutation. Both of the mutations have been identified in several ethnic 
groups, indicating a recurrent mutational event. In French-Canadian isolates, the 
mutation C26S is prevalent and a founder effect for this mutation has been 
suggested (81,97). Nearly all mutations are predicted to cause loss of function of 
malin (81,86,87). Mutations in the RING domains abolished malin’s ubiquitin 
ligase activity while those in the NHL motifs disrupted the interaction between 
malin and laforin (101). 
 
5.5. Phylogeny 
Laforin is conserved in all vertebrates, but it is absent from the genomes 
of most invertebrates, including Saccharomyces cerevisiae, Drosophila 
	   24 
melanogaster and Caenorhabditis elegans (102-104). Laforin is also conserved 
in five protozoans: Cyanidioschyzon merolae, Toxoplasma gondii, Eimeria 
tenella, Tetrahymena thermophile and Plasmodium tetraurelia, in the 
cephalochordate Branchiostoma floridae and in the cnidarian Nematostella 
vectensis (Figure 10) (103,104). The evolutionary lineage of laforin is unique. 
The five protozoan species undergo hibernation at some point in their life cycle 
wherein they form an insoluble glucan that resembles Lafora bodies (105). 
Niittyla et al. (106) described a gene in plants; starch excess 4 (SEX4), which 
encodes a protein containing an N-terminal DSPD and a C-terminal CBD, the 
same domains as in laforin but in the opposite orientation. SEX4 is a starch 
phosphatase and hydrolyzes C3 and C6 phosphate from amylopectin and the 
genetic depletion of SEX4 causes starch accumulation (15,106). Laforin 
complements the SEX4 phenotype in Arabidopsis, thus providing evidence that 
laforin and SEX4 are functional equivalents (103). Malin is present in all 
vertebrates and a cephalochordate (Figure 10) (107). Malin does not correlate 
with laforin in species distribution. Laforin is present in the genomes of 
evolutionarily more basal organisms, suggesting that laforin probably has 
function(s) independent of malin (107). 
 
	   
Figure 10. Phylogeny. Schematic representation of species distribution of laforin and malin. Laforin is 
present in the kingdoms plantae, protozoa and animalia whereas malin is present only in the kingdom 
animalia and is absent in the evolutionarily basal organisms. 
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6. Mouse Models of Lafora Disease 
Three mouse models for Lafora disease have been developed (90,108-
110). Targeted disruption of the mouse Epm2a gene resulted in viable null mice 
with most of the disease symptoms (109). It was initially reported that at two 
months of age, there was neuronal degeneration even in the absence of Lafora 
bodies. However, more recent work shows neuronal cell death at 11 days of age 
and type 1 Lafora bodies at 2 weeks of age (111). Type 1 Lafora bodies consist 
of granular, polymorphic, “dust-like”, uniformly stained particles. Type 2 Lafora 
bodies, which have a heavily stained core with a less stained circular rim on PAS 
stain, are prominent at 3 months of age and are present in both neuronal and 
non-neuronal tissues, are positive for ubiquitin and advanced glycogen end 
products (109). By 12 months of age, the mice have widespread neuronal 
degeneration, impaired behavioral responses, ataxia, myoclonus epilepsy and 
EEG epileptiform activity (109). The second mouse model transgenically 
overexpressed a dominant negative form of laforin, generated by mutating Cys 
266 to Ser, and thus inactivating the phosphatase (90). Lafora bodies were 
formed in the liver, muscle, neuronal perikarya and dendrites of these mice. 
Immunogold electron microscopy showed laforin in close proximity with 
endoplasmic reticulum and the surrounding polyglucosan accumulations (90). 
Mouse models with disruption of the Epm2b gene were generated by four 
independent studies (108,110,112,113). Targeted disruption of the gene resulted 
in viable mice that developed Lafora bodies in brain, heart and skeletal muscle 
by 3 months of age (108). The Epm2b-/- mice showed cognitive deterioration, 
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altered motor activity, impaired motor coordination, abnormal hind limp clasping 
and episodic memory deficits along with spontaneous single spikes, spike-wave, 
polyspikes, and polyspike-wave complexes with correlated myoclonic jerks 
(112,114). 
 
7. Disease Mechanism of Lafora Disease 
7.1. Laforin and Glycogen Metabolism 
A prominent hypothesis in causation of Lafora disease has been that 
Lafora bodies are formed as a result of an imbalance between the activities of 
glycogen synthase and branching enzyme. Laforin has been reported to bind to 
several proteins involved in glycogen metabolism such as glycogen synthase, 
GSK3, PTG, malin and the α2 and β2 subunits of AMPK (94,101,115-117). 
Independent studies have proposed that laforin might increase the activity of 
glycogen synthase (115,118). Two groups proposed that the inhibitory kinase, 
GSK3, is a laforin substrate (115,118). Dephosphorylation of GSK3 activates 
GSK3 to phosphorylate GS at multiple sites, thus keeping glycogen synthesis in 
check (Figure 12) (115). However, several studies argue against GSK3 being a 
laforin substrate (8,9,108,116,119). The phosphorylation state of GSK3 remains 
unchanged in the three different mouse models of Lafora disease: Epm2a-/- mice 
(8,9), dominant-negative laforin overexpressing mice (119) and Epm2b-/- mice 
(108). Wang et al. found no difference in the activities of glycogen synthase and 
branching enzyme in the brain tissue of dominant-negative laforin overexpressing 
mice (119). Glycogen synthase activity state was also unchanged in skeletal 
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muscle and brain of Epm2a-/- and Epm2b-/- mice (8,108), thus arguing against 
the hypothesis of imbalance in glycogen synthesis and branching as a cause for 
Lafora body formation. 
 
7.2. Laforin and Autophagy 
Glycogen autophagy or glycophagy has been described as a mechanism 
for disposal of glycogen (see above in section 3). Autophagy has also been 
shown to be essential for the function of the central nervous system. Impairment 
of autophagy leads to neurodegeneration, behavioral changes and death in 
murine models of diseases (120). Recently, Aguado et al. (121) and Criado et al. 
(112) proposed defects in laforin-malin complex-regulated autophagy as the 
primary cause of Lafora disease (see section 7.5). Laforin would activate 
autophagy by acting upstream of tuberous sclerosis complex 2 (TSC2) and 
inhibit mammalian target of rapamycin (mTOR) to activate autophagy (Figure 
12). Thus, in Lafora disease in the absence of laforin, mTOR would be activated 
inhibiting autophagy (121). 
 
7.3. Laforin as a Glycogen Phosphatase 
Worby et al. (116) demonstrated that laforin dephosphorylates 
amylopectin, the major component of plant starch. Amylopectin is similar to 
glycogen but with less frequent α-1,6 glycosidic linkages and contains phosphate 
in the form of C3- and C6-phosphomonoesters (13). Worby et al. (116) were 
unable to measure dephosphorylation of commercially available rabbit liver 
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glycogen by laforin. Tagliabracci et al. (9), however, showed that laforin can 
dephosphorylate rabbit muscle glycogen in vitro and was able to release ~25% of 
the phosphate from undigested rabbit muscle glycogen. Liver contains much 
lower levels of phosphate in glycogen as compared to muscle and this could 
explain why Worby et al. (116) were unable to measure dephosphorylation of 
glycogen in their experiment. Upon digestion with glucosidases, laforin released 
90% of the phosphate. Mutation of laforin in the CBD eliminated its ability to 
dephosphorylate glycogen. Glycogen isolated from Epm2a-/- mice, had a 40% 
increase in phosphate in liver and a 4-fold elevation in muscle by three months of 
age suggesting that glycogen is a physiological substrate of laforin (9). Electron 
microscopic analysis of glycogen purified from 9-12-month-old Epm2a-/- mice 
revealed the presence of large conglomerated aggregates with less granularity, 
more defined boundary and a more even density (8). This abnormal appearance 
of glycogen was reversed by laforin-dependent hydrolysis of phosphate in the 
glycogen (Figure 12) (8). 
 
7.4. Malin: an E3 Ubiquitin Ligase  
Malin is a potential E3 ubiquitin ligase with an N-terminal zinc finger RING 
domain (101). During ubiquitination, ubiquitin monomers are attached to the 
substrate protein in a three-step reaction: 1) activation of ubiquitin by an E1 
ubiquitin-activating enzyme in an ATP dependent manner; 2) E2 ubiquitin-
conjugating enzyme catalyzes the transfer of ubiquitin from E1 to the cysteine of 
the E2; and 3) E3 ubiquitin ligase recognizes the substrate and catalyzes the 
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formation of an isopeptide bond between the lysine of the substrate and the C-
terminal glycine of ubiquitin (Figure 11) (122,123). Ubiquitin is attached to the 
substrate at one lysine as mono-ubiquitination, at multiple lysines as multi-
ubiquitination or several ubiquitins at one lysine as poly-ubiquitination. The type 
of ubiquitination determines the fate of the substrate; for example poly-
ubiquitination at K48 of the ubiquitin targets the substrate for degradation by the 
ubiquitin proteasomal system whereas mono- or poly-ubiquitination at K63 of the 
ubiquitin controls gene transcription, DNA repair and intracellular trafficking 
(122,124) (Figure 11). 
Gentry et al. (101) reported that malin interacts with laforin and promotes 
its polyubiquitination resulting in degradation via the ubiquitin proteasomal 
pathway (Figure 12). Based on this model, defective malin should increase 
laforin protein levels. 
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Figure 11. Ubiquitination. An ubiquitin moiety is attached to the 
lysine of the substrate in a three-step reaction involving the 
enzymes ubiquitin-activating enzyme, E1, ubiquitin-conjugating 
enzyme, E2 and ubiquitin ligase, E3. The site of ubiquitination 
decides the fate of the substrate. 
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Patients with mutations in EPM2B (81) and Epm2b-/- mice have increased 
levels of laforin (108,110,112). If the physiological role of malin is to mediate the 
degradation of laforin, then it is difficult to understand how patients develop 
Lafora disease with recessive mutations in either EPM2A or EPM2B. Malin has 
also been reported to ubiquitinate and cause degradation of glycogen 
debranching enzyme, AGL, via the ubiquitin proteasomal pathway (Figure 12) 
(125). As a result of mutations in malin, increased AGL protein would remove the 
α-1,6 glycosidic linkages and lead to polyglucosan formation in Lafora disease. 
Lohi et al. (115) reported that malin binds and ubiquitinates glycogen synthase, 
and degrades it via the ubiquitin proteasomal pathway (Figure 12). Therefore, in 
Lafora disease, it was suggested that in the absence of the inhibitory affect of 
malin on glycogen synthase, polyglucosan is formed. However, in 3 months old 
Epm2b-/- mice, there is no change in the protein levels of AGL or glycogen 
synthase in skeletal muscle arguing against AGL and glycogen synthase being 
substrates for malin (108). 
 
7.5. Laforin-malin Complex 
Laforin and malin have been described to have a complex relationship. 
While they are reported to function together as a complex, malin also 
ubiquitinates laforin and promotes its degradation (101). Vilchez et al. (126) 
reported that laforin increases the stability of malin in spite of laforin being a 
malin substrate, further increasing the complexity in the relationship of the two 
proteins. One of the first proposed substrates of the laforin-malin complex was 
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PTG, a glycogen targeting subunit of protein phosphatase 1 (94,126,127). PP1 
activates glycogen synthase and inhibits glycogen phosphorylase. In this model, 
a laforin-malin complex would ubiquitinate and degrade PTG, thereby decreasing 
glycogen levels (Figure 12). In the absence of this complex due to mutations in 
either of the genes, Epm2a-/- or Epm2b-/-, glycogen synthase would be 
activated, thus forming polyglucosan. The protein level of PTG was unchanged in 
Epm2a-/- and Epm2b-/- mice, thus arguing against PTG being a malin substrate 
(108). Sharma et al. (128) reported neuronatin, a protein proposed to stimulate 
glycogenesis, as a novel substrate of the laforin-malin complex. The protein 
levels of neuronatin have not yet been evaluated in the mouse models. 
Besides regulating proteins involved in glycogen metabolism, the laforin-
malin complex has been proposed to play a role in protein clearance as well. 
Laforin and malin form a functional complex with the cellular chaperone Hsp70 to 
suppress the cytotoxicity of misfolded proteins, such as polyglutamine proteins 
and mutant α-synuclein (Figure 12) (129). It was proposed that laforin acts as a 
bridge between Hsp70 and malin, thus recruiting malin to ubiquitinate the 
misfolded proteins and target them for degradation via the proteasomal and/or 
autophagolysosomal pathway. The complex is suggested to function similar to 
other reported E3 ubiquitin ligases in protein clearance such as parkin (130), 
CHIP (carboxyl-terminal of Hsp70 interacting protein) (131), dorfin (132) and E6-
AP (133). The laforin-malin complex has also been shown to play a role in the 
regulation of autophagy (Figure 12). In cellular and mouse models of Lafora 
disease, in the absence of laforin or malin, autophagosome formation is 
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impaired. It was proposed that the absence of laforin or malin causes an 
accumulation of autophagic substrates leading to stress and eventually cell death 
(112,121). These defects further draw similarities to other neurological disorders 
such as Parkinson, Alzheimer’s or Huntington’s diseases, which also present 
with defects in autophagy (134). Vernia et al. (135) reported that the absence of 
laforin enhances the ER stress response in cells leading to proteasomal 
dysfunction and increased apoptosis, which might be an important causative 
factor for the development of Lafora disease. Thus, defects in the protein quality 
control pathway have been speculated to be a primary cause of Lafora disease. 
However, these results are inconsistent with those reported by Puri et al. (136) 
who found no changes in LC3-II or other autophagy proteins in brain lysates of 
laforin-deficient mice arguing that autophagosome formation and function is not 
abnormal in the brain of laforin-deficient mice. 
 
7.6. Malin as Transcriptional Regulator 
Laforin and malin have been shown to form a complex with the co-
chaperone CHIP, which improves the stability of malin (137). Sengupta et al. 
(138) demonstrated that the laforin-malin-CHIP complex translocates to the 
nucleus upon heat shock to interact with and activate HSF1 (heat-shock factor 
1), a transcription factor that activates the transcription of heat-shock genes to 
protect cells against stress-induced cell death (Figure 12). 
Malin has been reported to interact with dishevelled2, a key mediator of 
the Wnt signaling pathway (139). Malin promotes the K48- and K63- mediated 
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ubiquitination of dishevelled2, causes degradation via the proteasome and 
autophagy and thus, inhibits Wnt signaling in Lafora disease (Figure 12). An 
increase in Wnt signaling with malin mutations might lead to neurological defects 
such as synaptic plasticity and synaptic differentiation. 
 
7.7. Lafora Bodies: Cause or Consequence 
Lafora bodies are pathognomonic of Lafora disease, but there has been 
some debate as to whether Lafora bodies are the cause or consequence of 
Lafora disease. Turnbull et al. (140) generated the laforin-PTG-double knockout 
mice and analyzed the mice for phenotypes of Lafora disease. The PTG deficient 
mice, Ppp1r3c-/- mice have decreased glycogen synthase activity with 30% and 
70% reductions in muscle and brain glycogen, respectively. In laforin-PTG-
double knockout mice, glycogen accumulation and the number of Lafora bodies 
were dramatically decreased and the neurological symptoms due to the absence 
of laforin were alleviated (140). Further, recent studies by Pederson et al. (141) 
and Duran et al. (142) showed that inhibiting glycogen synthesis in laforin and 
malin knockout mice prevents the development of symptoms of Lafora disease 
(141). Taken together, these studies indicate that the primary defect in Lafora 
disease is the accumulation of insoluble, poorly branched polyglucosan. 
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Figure 12. Mechanisms for Causation of Lafora Disease. 
Schematic representation of defects in glycogen metabolism 
(colored purple), protein quality control (colored blue) or 
transcriptional regulation (colored orange) in Lafora disease. AGL, 
debranching enzyme; CHIP, carboxyl-terminus of Hsp70 interacting 
protein; Dvl2, dishevelled 2; GSK3, glycogen synthase kinase 3; 
Hsp70, heat shock protein 70; HSF1, heat shock factor 1; mTOR, 
mammalian target of rapamycin; PTG, protein targeting to 
glycogen; PP1, protein phosphatase 1; Pi, phosphate. 
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RESEARCH OBJECTIVE 
Lafora disease is a fatal neurodegenerative disorder with no cure available 
yet. The focus of Lafora disease research has been to understand the 
physiological role of the laforin phosphatase and the malin ubiquitin ligase in the 
etiopathogenesis of the disease, which might lead to identification of therapeutic 
targets. Previous work showed that laforin acts as a glycogen phosphatase and 
in the absence of laforin, in mouse models of Lafora disease, there is an increase 
in glycogen phosphorylation. Overall, it has been proposed that the laforin-malin 
complex plays a role in the regulation of glycogen metabolism and protein quality 
control. In this study, my focus was on two main aims: 
1. To understand the role of laforin and malin in the protein 
degradation/quality control process, I evaluated the three different arms: the 
autophagolysosomal pathway, the ubiquitin-proteosomal pathway and the ER 
stress response. 
2. To understand the precise role of malin in the causation of Lafora disease, 
I used an unbiased quantitative proteomics approach in an attempt to identify the 
physiological substrate(s) of malin. 
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EXPERIMENTAL PROCEDURES 
1. Animals 
The Epm2a-/- and Epm2b-/- mice have been previously described 
(108,143). Epm2a-/- and Epm2b-/- mice were intercrossed to generate double 
heterozygous Epm2a+/- Epm2b+/- mice, which were then crossed to generate 
the double Epm2a-/- Epm2b-/- mice. All mice were maintained in temperature- 
and humidity-controlled conditions with a 12:12-hour light-dark cycle, fed a 
standard chow (Harlan Teklad global diet 2018SX) and allowed food and water 
ad libitum. All studies were conducted in accordance with Federal Guidelines, 
and were approved by the Institutional Animal Use and Care Committee of 
Indiana University School of Medicine. 
 
2. Generation of Mouse Embryonic Fibroblasts (MEFs) 
On day 0 evening, breeders for each genotype were set up with one adult 
male and two adult females. The females were examined for the presence of a 
vaginal plug the following morning. The age of the embryo was recorded as day 
0.5 when the plug was present. The male mouse was removed from the cage. 
The female mice were euthanized on day 13.5 by cervical dislocation and the 
uterus along with the embryos was dissected out. The embryos were harvested 
from the uterus under aseptic conditions. The head of the embryo was removed, 
the remainder was cut up into small pieces in 1 ml of 1X phosphate-buffered 
saline (PBS) (137 mM sodium chloride, 10 mM disodium phosphate, 2.7 mM 
potassium chloride, 1.8 mM monopotassium phosphate, pH 7.4) and a single-cell 
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suspension was created by sequentially passing the material through 16-, 18- 
and 20-gauge needles using a 2 ml syringe. The cell suspension was centrifuged 
at 2000 X g for 5 minutes at room temperature. The supernatant was saved for 
genotyping (described below) and the cell pellet was washed once with 1X PBS 
and then resuspended in 10 mL of Dulbecco’s Modified Eagle Medium:Nutrient 
Mixture F12 (DMEM-F12) (Hyclone) supplemented with 10% fetal bovine serum 
(FBS) (Thermo Fisher Scientific), 100 units/ml of penicillin (Sigma) and 100 µg/ml 
of streptomycin (Sigma). The cells were plated in 100 mm tissue culture dishes 
and incubated at 37oC with 5% CO2 in a humidified incubator. 
 
3. Genotyping of the MEFs 
Embryos were generated by crossing appropriate homozygous parents; 
Epm2a-/-, Epm2b-/- and double Epm2a-/- Epm2b-/- mice. The genotype of the 
resulting MEFs was confirmed by PCR as described before (108) (Figure 13). 
Figure 13. Genotyping of the Mouse Embryonic Fibroblasts. 
Mouse embryonic fibroblasts (MEFs) derived from Epm2a-/- (Laf 
KO), Epm2b-/- (Mal KO) and double Epm2a-/- Epm2b-/- (Laf-Mal 
KO) mice were genotyped by PCR. A) “Laf Het” is the control 
showing alleles for both wild type and mutant laforin loci. B) “Mal 
Het” is the control showing alleles for both wild type and mutant 
malin loci. WT; wild type, M; marker. 
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4. Mammalian Cell Culture 
MEFs were seeded at a cell density of around 1.5 x 106 cells/100-mm 
plate, grown till 85-90% confluence and then passaged in a 1:3 ratio for 
propagation. MEFs between passage 3 and 8 were used for all experiments. 
Under basal conditions the MEFs were cultured in DMEM-F12 medium 
supplemented with 10% FBS, 100 units/ml of penicillin and 100 µg/ml of 
streptomycin (full medium) at 37oC with 5% CO2 in a humidified incubator. 
To culture cells under starvation conditions, cells were washed twice with 
PBS at room temperature and switched from full growth medium to Earle’s 
balanced salt solution (EBSS from Sigma) and incubated for 2 hours at 37oC with 
5% CO2 in a humidified incubator. Cell extracts were prepared at the time of 
harvest as described below in section 10. 
For inhibition of lysosomes, MEFs were incubated with medium that 
contained 20 µM chloroquine for 2 hours. For studies of autophagy, MEFs were 
treated with 10 nM rapamycin, an inhibitor of mTOR for 2 hours. For inhibition of 
proteasomal function, MEFs were incubated with medium that contained 20 µM 
MG132 for 2 hours. To measure ER stress responses, MEFs were incubated 
with medium that contained 1 µM thapsigargin or 2 µg/ml tunicamycin for 18 
hours. In control experiments, MEFs were incubated in medium that contained 
vehicle, dimethyl sulfoxide or sterile distilled water as appropriate. Cell extracts 
were prepared at the time of harvest as described below in section 10. 
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5. Stable Isotope Labeling with Amino Acids in Cell Culture 
MEFs from Epm2b-/- mice and their wild-type controls were grown in 
lysine- and arginine-free DMEM-F12 medium supplemented with 10% or 2% 
dialyzed FBS, 100 units/ml of penicillin and 100 µg/ml of streptomycin. The 
medium was also supplemented with either [12C614N2] lysine (K0) and [12C614N4] 
arginine (R0) (light medium) or [13C615N2] lysine (K8) and [13C615N4] arginine 
(R10) (heavy medium). The concentration of lysine (90 µg/ml) and arginine (148 
µg/ml) was the same in both light and heavy medium. The cells were grown for at 
least for 5 passages in an effort to ensure complete labeling with heavy lysine 
and arginine. In most cases, the cells were grown for 7-8 passages over 4-5 
weeks to obtain enough starting material (45-50 mg of protein). Cells, in both 
light and heavy medium, were incubated with medium containing 20 µM MG132 
for four hours before the time of harvest. The cells were harvested as described 
below in section 14.1. 
 
6. Culturing MEFs in Serum-free Medium 
The cells were cultured in full medium and then adapted to serum-free 
media by either direct adaptation or sequential adaptation. FibroGRO™ 
Complete Media Kit (Millipore) was used as a serum-free alternative for growing 
mouse embryonic fibroblasts. The medium contains FibroGRO Basal Medium 
and supplements including 5 ng/ml of basic fibroblast growth factor, 5 ng/ml of 
epidermal growth factor, 30 pg/mL of transforming growth factor-β1, 500 µg/mL 
of human serum albumin, 0.6 µM linoleic acid, 0.6µg/mL of lecithin, 50 µg/ml of 
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ascorbic acid, 7.5 mM L-glutamine, 1 µg/ml of hydrocortisone hemisuccinate and 
5 µg/ml insulin. The cells were initially grown in DMEM-F12 medium with 10% 
FBS and then switched directly to the serum-free alternative medium. For 
sequential adaptation, the cells were initially grown in DMEM-F12 medium with 
10% FBS (Full medium) and then switched to the serum-free alternative medium 
(SFM) through several sequential steps. This involved increasing the ratio of 
SFM to Full medium at sequential passages from 0:100, 30:70, 50:50, 70:30, 
80:20, 90:10 to 100:0. 
 
7. Culturing MEFs in Low Serum Medium 
The cells were initially grown in DMEM-F12 medium with 10% FBS (Full 
medium) and then switched to the DMEM-F12 medium with reduced serum 
through several sequential steps. This involved switching the concentration of 
FBS at sequential passages from 10%, 7.5%, 5%, 2% to 1%. The concentration 
of antibiotics was reduced from 100 units/ml of penicillin and 100 µg/ml of 
streptomycin to 20 units/ml of penicillin and 20 µg/ml of streptomycin. 
 
8. Rinsing and Washing Techniques for MEFs 
MEFs were cultured in DMEM-F12 medium supplemented with 10% FBS 
and 100 units/ml of penicillin and 100 µg/ml of streptomycin (full medium). At the 
time of harvest, the cells were rinsed by different techniques. The culture medium 
was removed completely by aspiration while the plates were on ice. The plates 
were then rinsed three times with either 10 ml of ice cold PBS on ice, on an 
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orbital shaker at 4oC for 5 minutes or with 10 ml of DMEM-F12 medium without 
FBS on an orbital shaker at 4oC for 5 minutes. The cells were also washed in 
suspension after tryspinization. The cells were detached from the plate surface 
and full medium was added to inactivate trypsin activity followed by centrifugation 
at 2000 X g for 5 minutes. The supernatant containing the medium was 
discarded and the cell pellet was washed three times for 5 minutes with 10 ml of 
ice-cold Dulbecco’s phosphate buffered saline with calcium and magnesium on a 
nutator at 4oC. Following the washes, cell lysates were prepared as described 
below in section 10. 
 
9. Chemicals, Antibodies and other Reagents 
Chloroquine was from Sigma. Rapamycin was from LC Laboratories. 
Thapsigargin, tunicamycin and MG132 were from Cayman Chemicals. Antibody 
sources were as follows: Anti-LC3, anti-Phospho-S6K, anti-S6K, anti-Phospho-
S6, anti-S6 were from Cell Signaling Technology; anti-GABARAPL1, anti-CHOP 
were from Protein Tech Group; anti-LAMP1, anti-S5a subunit of 26S Proteasome 
were from Iowa Hybridoma; anti-Ubiquitin was from Millipore; anti-
glyceraldehyde-3-phosphate dehydrogenase was from Biodesign International; 
anti-Stbd1 has been previously described (33). HEPES, CAM, TCEP and NEM 
were from Sigma. Trypsin-Gold was from Promega. Lys-C was from Roche. Sep-
Pak® C18 columns were from Waters. StageTips (C18) and trifluoroacetic acid 
were from Thermo Scientific. Acetonitrile was from Thermo Fisher Scientific. 
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Other chemicals and reagents were from Sigma, Bio-Rad, Invitrogen or New 
England Biolabs. 
 
10. Western Blot Analysis 
Cells were washed three times with ice-cold PBS and then lysed with ice-
cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl 
sulphate, 1% sodium deoxycholate and 1% nonidet-P40) for 15 minutes in 
presence of protease inhibitors (1mM phenylmethylsulfonyl fluoride (PMSF), 0.1 
mM N-p-tosyl-1-lysine chloromethyl ketone (TLCK), 1 mM benzamidine, 1 µg/ml 
aprotinin, pepstatin and leupeptin). The cell lysates were centrifuged at 10,000 X 
g for 15 minutes at 4oC to pellet insoluble materials. For detection of LC3 and 
GABARAPL1, cells were lysed with ice-cold RIPA buffer with 0.5% sodium 
dodecyl sulphate for 15 minutes in the presence of protease inhibitors as 
described above. Protein concentration was determined by the Bradford method 
using bovine serum albumin as a standard (144). The supernatants of the lysates 
or total lysates (for LC3 and GABARAPL1) were diluted with 5 X loading buffer 
(62.5 mM Tris-PO4 pH 6.8, 50% (w/v) glycerol, 6.25% (w/v) SDS, 0.1% (w/v) 
bromphenol blue and 5% β-mercaptoethanol) to 1 X and boiled for 10 minutes.  
Samples of 10 µg protein from MEFs were separated on 10% SDS 
polyacrylamide gel electrophoresis (PAGE) and transferred onto a 0.45 µm 
nitrocellulose membrane (Biorad) at 15 V overnight. For detection of LC3, 10 µg 
protein were separated on 15% SDS-PAGE at room temperature and transferred 
onto a 0.22 µm polyvinylidene fluoride (PVDF from Millipore) membrane at 100 V 
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for 90 minutes at 4oC. After transfer, the nitrocellulose membranes were stained 
with Ponceau S (0.5% Ponceau S in 1% glacial acetic acid) to monitor loading 
followed by blocking in 5% non-fat milk powder in 1X tris-buffered saline (TBS) 
(50mM Tris-HCl, 150 mM sodium chloride, pH 7.6) with 0.1% Tween 20 or 5% 
BSA in 1X TBS with 0.1% Tween 20 (for anti-LC3, anti-phospho-S6K, anti-S6K, 
anti-phospho-S6 and anti-S6 antibodies). The membranes were probed with 
various primary antibodies (diluted in 2% non-fat milk powder in 1X TBS with 
0.1% Tween 20 or 5% BSA in 1X TBS with 0.1% Tween 20 for PVDF) for 2 hours 
at room temperature or overnight at 4oC followed by three 10 minutes washes 
with 1X TBS with 0.1% Tween 20. Incubation with horseradish peroxidase-
conjugated-secondary antibodies (diluted in 2% non-fat milk powder in 1X TBS 
with 0.1% Tween 20 or 5% BSA in 1X TBS with 0.1% Tween 20 for PVDF) was 
done for 1 hour at room temperature followed by three 15 minute washes with 1X 
TBS with 0.1% Tween 20. Detection was performed by enhanced 
chemiluminescence using Pierce ECL Western blot substrate or Millipore 
Immobilon Western substrate (for anti-ubiquitin antibody). The levels of proteins 
were quantitated by densitometric analysis of the autoradiograph using 
CareStream software. Phospho-specific antibodies were used first during 
immunoblotting. The membranes were treated with stripping buffer (62.5 mM 
TrisCl pH 6.8, 2% SDS, 0.7% β-ME) for 40 minutes at 55oC and then probed for 
the total protein of interest. 
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11. Staining of SDS-PAGE gel with Coomassie Blue 
To prepare the Coomassie Blue stain, glacial acetic acid (100 mL) was 
added to 500 mL of water. To this, 400 mL of methanol was added and mixed 
well. Coomassie R250 dye (1 g) was added to the solution and mixed till 
completely dissolved. The stain solution was filtered to remove any undissolved 
particulates. Destaining solution consisted of 10% (v/v) acetic acid, 20% (v/v) 
methanol. After electrophoresis, the SDS-PAGE gel was removed from its glass 
plates and rinsed once in water. Coomassie blue stain was added such that the 
stain covered the gel completely. The gel was incubated for 20 minutes on an 
orbital shaker at room temperature. The Coomassie stain was poured off and the 
gel was rinsed twice with destaining solution. Destaining solution was added to 
cover the gel completely. Kimwipes®, which bind the Coomassie dye, were rolled 
up into small balls and placed in the destaining solution around the gel. The gel 
was incubated in the destaining solution overnight at room temperature. 
 
12. Quantitation of Proteasomal Activity 
Chymotrypsin-like activity of the proteasome was evaluated using the 
Proteasome-Glo™ Assay Reagent (Promega). The reagent contains a 
luminogenic substrate of the proteasome, Suc-LLVY-aminoluciferin (145). 
Incubation with soluble cellular protein extracts is used to measure proteasome 
activity. Substrate cleavage generates a “glow-type” luminescent signal produced 
by the luciferase reaction (Ultra-Glo™ recombinant luciferase) (Figure 14). The 
signal thus generated is proportional to the amount of activity of the proteasome. 
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Figure 14. Proteasomal Activity. The luminogenic substrate 
contains the Suc-LLVY sequence that is recognized by the 
chymotrypsin-like activity of the proteasome. Upon cleavage by the 
proteasome, aminoluciferin generates the luminescent signal in a 
reaction catalyzed by luciferase enzyme. 
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Proteasome-Glo™ Buffer, the lyophilized Luciferin Detection Reagent and 
the Suc-LLVY-Glo™ Substrate were equilibrated to room temperature. The 
Luciferin Detection Reagent was reconstituted with 10ml of Proteasome-Glo™ 
buffer. The Proteasome-Glo™ Reagent was prepared by adding the 
Proteasome-Glo™ Substrate to the reconstituted Luciferin Detection Reagent. 
The Reagent was left at room temperature for at least 60 minutes before use. 
This allows the removal of any contaminating free aminoluciferin. MEFs from wild 
type, Epm2a-/-, Epm2b-/- and double Epm2a-/- Epm2b-/- mice were harvested 
and soluble protein extract was prepared as described above in section 10. The 
cell extracts were diluted in water such that 25 uL corresponded to 10 µg of 
soluble protein. Proteasome-Glo™ Reagent (25 µL) was added to each well of a 
white walled, clear-bottom, flat-bottom, half area 96-well plate. To each well, 25 
µL of soluble protein extract was added. The contents of the plate were mixed 
using a plate shaker at 300-500 rpm for 30 seconds followed by incubation at 
room temperature for 15 minutes. Chymotrypsin-like proteasomal activity was 
detected by measuring the relative light units (RLU) using a SpectraMax M5 
Luminometer (Molecular Devices). 
 
13. Measurement of Glycogen Levels in MEFs 
Total glycogen in the MEFs was assayed by slight modifications of the 
method described by Suzuki et al. (146). MEFs were seeded in 100-mm cell 
culture plates in DMEM:F12 medium (full medium) as described above and 
grown till 100% confluence. The cells were grown for 7 days and supplemented 
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with fresh medium every day. At the time of harvest, the total lysate was 
prepared as described above in section 10, collected in a 1.5 mL screw cap tube 
and freshly prepared hot 50% KOH was added to a final concentration of 30%. 
The lysate was boiled for 30 minutes, mixing by inverting the tubes every 5-10 
minutes. The samples were cooled on ice 2% Na2SO4 (w/v) and 2 volumes of 
100% ethanol were added and incubated at -20oC overnight to precipitate the 
glycogen. After precipitation, the glycogen was collected by centrifugation at 
17500 X g for 20 minutes, resuspended in 100 µL of water and precipitated again 
by addition of 2 volumes of 100% ethanol at -20oC for 1 hour. This procedure 
was repeated one more time, the last and third precipitation going overnight. The 
glycogen pellet after each precipitation was dried in a SpeedVac. The glycogen 
was digested to glucose either enzymatically with amyloglucosidase or with 
hydrochloric acid as described below. For enzymatic digestion, the glycogen 
pellet was digested overnight with 100 µL of amyloglucosidase in 0.2 mM sodium 
acetate pH 4.8 (final concentration 0.3 mg/ml). For acidic digestion of glycogen, 
100 µL of 2 N hydrochloric acid was added to the glycogen pellet, boiled for 2 
hours and then cooled on ice. The acid was neutralized with 2 N NaOH in the 
presence of 0.1 M Tris HCl pH 7.0. After the digestion, the samples were 
centrifuged at 17500 X g for 5 minutes and the supernatant collected in a new 
tube. The supernatants were stored at -20oC till use. Glucose equivalents were 
determined by a coupled reaction involving the conversion of glucose to glucose-
6-phoshate by hexokinase and reduction of nicotinamide adenine dinucleotide 
phosphate (NADP+) by glucose-6-phosphate dehydrogenase and measuring the 
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OD at 340 nm. Typically, 10 µL of digested glycogen was added to a 300 uL 
reaction mix (300 mM triethanolamine pH 7.6, 4 mM MgCl2, 0.9 mM NADP+, 2 
mM ATP and 2 µg/mL glucose-6-phosphate dehydrogenase (Roche)). An aliquot 
(100 µL) was taken from the reaction mix and the OD at 340 nm was recorded 
(blank). To the remaining 200 µL, 5 µL of hexokinase (1 mg/mL stock, Roche) 
(diluted 1:10 in 3.2M (NH4)2SO4) was added and the reaction was allowed to 
proceed at room temperature for 30 minutes. The OD at 340 nm was recorded 
(147). Glycogen content is expressed as µmol of glucose/mg of protein. 
 
14. Sample Preparation for Mass Spectrometric Analysis 
14.1. Preparation of Cell Lysates 
MEFs from Epm2b-/- mice and their wild-type controls were grown in light 
or heavy medium as described above in section 5. At least ten 150-mm cell 
culture plates grown to about 90% confluence were used for each genotype. The 
medium was aspirated from the each plate and the plate was kept tilted for 30 
seconds so that the remaining medium flows to the bottom edge that was also 
aspirated. The plate was washed with at least 15 ml of cold PBS three times. 
During removal of medium and washes, the plate was kept on ice. After washing, 
the plate was brought to room temperature and 10 ml of denaturing lysis buffer, 
containing 20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerophosphate and 5 mM N-
ethylmaleimide, was added. The lysis buffer was prepared fresh prior to each 
experiment. The cells were scraped into the buffer to the bottom edge of the 
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plate. The sample was transferred to the second plate and the process was 
repeated for all the plates of the same genotype. The same process of washing 
and lysis was repeated for all the plates of the second genotype. The yield for all 
genotypes was around 12-15 ml of lysate. Using a microtip, each lysate was 
sonicated three times for 30 seconds each using Ultrasonic Processor (from 
Misonix Incorporated). The lysate was centrifuged at 20,000 X g for 15 minutes 
at room temperature and the protein extract (supernatant) was transferred to a 
new tube. Protein concentration was determined by the Bradford method using 
BSA as standard (144). Extracts from cells labeled with light or heavy amino 
acids were mixed in a 1:1 ratio according to the protein concentration. About 20 
µg of the total extract was saved for analysis by mass spectrometry as an 
internal control to determine the heavy:light ratio. 
 
14.2. Preparation of Tissue Homogenates  
Random fed 6-month-old male wild type and Epm2b-/- mice were 
sacrificed by cervical dislocation. The animals were decapitated and the heads 
immediately dropped in liquid nitrogen, and skeletal muscles were dissected and 
immersed in liquid nitrogen. Frozen tissue was pulverized under liquid nitrogen 
and stored at -80oC until use. Around 800 mg of frozen muscle from mice of each 
genotype was homogenized in 20 volumes (w/v) of denaturing lysis buffer, 
containing 20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerophosphate and 5 mM N-
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ethylmaleimide (NEM) with a tissue tearer for 30 seconds. Protein concentration 
was determined by the Bradford method using BSA as standard (144). 
 
14.3. Reduction and Alkylation of the proteins 
To the tissue lysate 0.1 M Tris(2-carboxyethyl)phosphine (TCEP) was 
added to a final concentration of 5 mM and incubated at room temperature for 30 
minutes. This was followed by addition of 0.5 M carboxyacetamide (CAM) to a 
final concentration of 10 mM and incubated for 30 minutes at room temperature 
in the dark to alkylate the cysteines. 
 
14.4. Protein Digestion 
After reduction and alkylation, the lysate was diluted with 20 mM HEPES 
pH 8.0 to a final concentration of 2 M urea. Calcium chloride (CaCl2) (1 M) was 
added to a final concentration of 2 mM and sequencing-grade trypsin (Promega) 
was added in an enzyme-substrate ratio of 1:200 and incubated overnight at 
37oC with shaking. The enzymatic digestion was terminated by addition of 20% 
trifluoroacetic acid (TFA) to a final concentration of 1%. The pH of the peptide 
solution was checked (should be less than 3). The acidified peptide solution was 
kept on ice for 15 minutes to allow any precipitate to form. The precipitates were 
removed by centrifugation at 1800 X g at room temperature for 15 minutes and 
the supernatant was transferred to a new tube. 
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14.5. Purification of Lysate Peptides 
The acidified cleared peptides were purified using C18 Sep-Pak® columns 
(Waters). The column size was chosen such that the binding capacity of the 
SepPak® column is at least 2 times higher than the total amount of sample 
loaded to prevent any loss. All solutions were applied by gravity flow and the 
application of vacuum was avoided. For conditioning and washes, 5-10 column-
volumes were used. The column was pre-wet with 100% acetonitrile and washed 
with 0.1% TFA. After washing, the acidified cleared peptides were loaded 
followed by sequential washes with 0.1% TFA and 5% acetonitrile, 0.1% TFA. 
The peptides were eluted with at least two column-volumes of 60% acetonitrile, 
0.1% TFA. The eluate from each genotype was collected in a fresh tube and 
frozen on dry ice (or -80oC) for at least 2 hours or overnight. The frozen peptides 
were freeze-lyophilized for a minimum of 3 days to assure complete removal of 
TFA from the peptide sample using a Labconco lyophilizer. 
 
14.6. Immunoaffinity Purification of diGly Peptides 
The lyophilized peptides were resuspended in 1.4 mL of immunoaffinity 
purification (IAP) buffer (50 mM MOPS/NaOH pH 7.2, 10 mM disodium 
phosphate, 50 mM NaCl) by pipetting repeatedly with a P-1000 micropipettor, 
avoiding introduction of excessive air bubbles into the solution. The resuspended 
peptides were transferred into a new 1.5 ml tube. The pH of the solution was 
maintained close to neutral or no lower than 6.0. If the pH was low, it was 
adjusted by addition of 1 M Tris base solution (10-20 µl). The resuspended 
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peptide solution was cleared by centrifugation at 10000 X g for 5 minutes at room 
temperature. The supernatant was collected in a fresh tube and cooled on ice. 
The diGly antibody-bead slurry (80 µl) was sequentially washed with 1 ml 
1X PBS four times and resuspended in 40 µl PBS. The peptide solution (1.4 mL) 
was transferred to the beads. The peptide-bead mix was incubated on a nutator 
for 3 hours at 4oC. Before incubation, the microfuge tube containing the peptide-
bead mix was sealed with parafilm to prevent leakage. After 3 hours, supernatant 
was collected after centrifugation at 2000 X g for 30 seconds and transferred to a 
new tube. The beads were washed with IAP buffer twice followed by three 
washes with water. Each time 1 ml of IAP buffer or water was added and mixed 
by inverting tube 5 times followed by centrifugation at 2000 X g for 30 seconds. 
After the last wash, the beads were centrifuged for 5 seconds and all remaining 
supernatant was removed. Elution was performed by incubation with 100 µl of 
0.15% TFA at room temperature for 10 minutes, mixing by tapping every 2-3 
minutes followed by centrifugation at 2000 X g for 30 seconds. The step was 
repeated with 100 µl of 0.15% TFA and both eluates were combined. 
 
14.7. On-column Labeling of Peptides. 
For some samples, eluates from the IAP were immobilized and then 
labeled on C18 Sep-Pak® columns (Waters). The column was prepared as 
described above. After loading the sample (IAP eluate) the column was flushed 
with the respective on-column labeling reagents as described below. To ensure 
complete labeling, the labeling reagent was passed through the column over at 
	   55 
least 30 minutes. Labeling reagent (200 mL) was used for 200 µg of protein 
sample. The labeling reagents were prepared by an adaptation of the protocol of 
Boersema et al. (148). Sodium phosphate buffer pH 7.5 (50 mM) was prepared 
by mixing 40 mL of 50 mM NaH2PO4 with 140 mL of 50 mM Na2HPO4. To this, 
10 mL of 4% (v/v) formaldehyde in water (CH2O or CD2O) and 10 mL of 0.6 M 
cyanoborohydride in water (NaBH3CN) was added at a final concentration of 65 
mM formaldehyde and 30 mM cyanoborohydride. It is important to note that the 
concentrations of the light and heavy formaldehyde as supplied by the 
manufacturer (Sigma) are different: 37% (w/v) light formaldehyde and 20% (w/v) 
deuterated formaldehyde. The labeling reagent mixtures were kept at 4oC and 
used fresh (within 24 hours) to ensure complete labeling. After labeling, the 
columns were sequentially washed with 0.1% TFA and 5% acetonitrile, 0.1% 
TFA. The labeled peptides were eluted with 2 column volumes of 80% 
acetonitrile, 0.1% TFA and then freeze lyophilized overnight. The differentially 
labeled peptides were mixed and the sample was analyzed by mass 
spectrometry as described below. 
 
14.8. Mass Spectrometry Analysis and Data Processing 
14.8.1. Multidimensional Protein Identification Technology 
Following diGly antibody immunoaffinity purification, optional dimethyl 
labeling and elution, peptides were analyzed using an adapted multidimensional 
protein identification technology (MudPIT) protocol in collaboration with the 
Mosley laboratory in the Department of Biochemistry and Molecular Biology at 
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IUSM, Indianapolis. MudPIT is the method of choice for analyzing complex 
protein samples. In brief, two different chromatographic resins are used to 
improve the resolving power of the chromatography since each separation 
methods uses different molecular properties as a basis for separation. A strong 
cation exchange resin (SCX), which binds positively charged compounds, is the 
first dimension of the separation, occupying approximately 2.5 – 3 centimeters in 
a 100 micron nanocolumn. The second dimension of separation is a reverse-
phase C18 resin that will separate peptides based on their hydrophobicity 
(149,150). The peptides are eluted off the SCX resin using ammonium salts in 
sequential steps starting from low to high salt concentration. After each step, 
some peptides will be released from the SCX resin and will bind to the C18 resin. 
The salt step is followed by a gradient of acetonitrile (organic) buffer to elute the 
peptides from the C18 resin and directly into the mass spectrometer. Following 
previous studies in the Mosley laboratory (151), a 10-step MudPIT experiment 
was performed using 8 µL of the following concentrations of ammonium acetate 
in sequential steps to elute subsets of peptides from the strong cation exchange 
resin (Luna 5µM SCX, Phenomenex): 5 mM, 10 mM, 25 mM, 50 mM, 100 mM, 
150 mM, 200 mM, 250 mM, and 300 mM (performed twice) followed by a 120-
minute gradient of 5-60% acetonitrile. Considering that ubiquitination reduces the 
likelihood of trypsin cleavage at the modified lysine residue and that the N-
terminus of the diGly remnant retains a positive charge, the majority of the diGly 
modified peptides have a net charge of ≥ +3. During the initial pilot experiments 
for this study, we determined that the diGly remnant peptides eluted late in the 
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standard 10-step MudPIT. To provide greater chromatographic resolution for 
these peptides and to allow for their complete elution, we employed a modified 
MudPIT experimental protocol for these analyses using 8 µL of the following 
concentrations of ammonium acetate in sequential steps to elute subsets of 
peptides from the strong cation exchange resin: 25 mM, 50 mM, 75 mM, 100 
mM, 150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM. Additionally, the 
organic gradient of 5-60% acetonitrile was increased to 140 minutes. This 
approach, henceforth referred to as diGly MudPIT, was used to analyze dimethyl-
labeled and unlabeled samples. 
 
14.8.2. Mass Analysers 
Using the diGly MudPIT approach, technical replicates of the samples 
were analyzed on a LTQ Velos Pro ion trap, a LTQ Velos Pro Orbitrap, or a Q-
Exactive mass spectrometer as indicated. Ion trap mass spectrometers are high-
throughput instruments that feature fast scan rates, high sensitivity and 
reasonable resolution and mass accuracy (100 ppm) (152). Orbitrap uses orbital 
trapping of ions in its electrostatic fields (153) in which ions orbit around a central 
electrode and oscillate in the axial direction. The Orbitrap mass analyzer has 
high resolution, high mass accuracy (2-5 ppm), a mass-to-charge range of 6000 
and a dynamic range greater than 103. The Q-Exactive mass spectrometer is the 
combination of a quadrapole mass filter with the Orbitrap analyzer and has better 
than 1 ppm mass accuracy (154). Peptides are traditionally fragmented by 
collision induced dissociation (CID) fragmentation (155) and this method was 
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employed on both the Velos Pro instruments. The data acquired on the Q-
Exactive instrument all used higher-energy collision induced dissociation (HCD) 
fragmentation for MS/MS peptide analysis. The fragmentation events normally 
occur at the peptide bonds and some fragmentations occur more frequently than 
others as a consequence of individual amino acid characteristics resulting in 
variation in the abundance of the peaks in MS/MS spectra. The fragment peaks 
that contain the amino-terminus of the starting peptide (parent) are termed b-ions 
while those containing the carboxy-terminus are called y-ions. In Figure 15, the 
b-ion series is in red and the y-ion series is in blue. The amino acid sequence of 
sections of the fragmented peptide can be inferred by the mass difference 
between the fragment peaks, for example the mass difference between y10 and 
y11 is the mass of glutamic acid (Figure 15 B). The mass of the precursor ion is 
also used to identify the sequence of the peptide when compared to a protein 
database. MS/MS data were collected during the MudPIT separation as outlined 
above using Xcalibur software (Thermo Scientific). For each sample, data was 
collected using data dependent acquisition with the top 20 most intense ions 
being selected for MS/MS analysis following collision induced dissociation (CID) 
or higher-energy collision induced dissociation (HCD) fragmentation. Dynamic 
exclusion settings were as follows: LTQ Velos Pro = 90 seconds, LTQ Velos Pro 
Orbitrap = 75 seconds, Q-Exactive = 50 seconds; with a repeat count of 1. MS1 
data were collected on the LTQ Velos Pro Orbitrap and the Q-Exactive with a 
resolution of 60,000. MS/MS analysis in the Q-Exactive was analyzed in the 
Orbitrap with a resolution of 7,500. The use of high-resolution instruments for 
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some technical replicates of each sample was performed to aid in confirmation of 
the peptide identification. 
 
14.8.3. Peptide Identification 
Peptide identification is performed by correlating the acquired MS/MS 
spectra from the experiment with theoretical spectra predicted for each peptide in 
a protein sequences database using a number of available computational tools. 
The program takes the experimental MS/MS spectrum as the input and 
generates a score after comparison against the theoretical fragmentation 
spectra. The search score calculated by the program measures the number of 
fragment ion matches between the experimental and theoretical spectra for 
peptides from the FASTA database with similar precursor ion masses. All RAW 
files from the respective mass spectrometers were used for FASTA database 
searches using Proteome Discoverer 1.4, which is licensed for use of SEQUEST 
HT as the database search algorithm. A beta version of Percolator 64 was used 
for target-decoy based false discovery rate calculations as previously described 
(156). All searches were performed using the mouse Uniprot FASTA proteome 
for peptide-spectrum matching. A peptide-spectrum match (PSM) scoring 
function counts the number of times a peptide-spectrum pair matches the 
fragmentation pattern of a peptide in the database (157). The database also 
contained ~150 common contaminant proteins including keratins, IgGs, and 
proteolytic enzymes. In all searches, modification of cysteine by NEM was 
included as a static modification (+125.13 dalton). Dynamic modifications applied 
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in every search included methionine oxidation (+15.999 dalton) and diGly 
remnant on lysine (+114.1 dalton). Specific modifications included for dimethyl 
labeling experiments include: static N-terminal light methylation (+28 dalton) with 
dynamic heavy labeling (+4 dalton), lysine light methylation (+28 dalton), lysine 
heavy methylation (+32 dalton), diGly remnant with light labeling of the free 
glycine N-terminus (+142 dalton), and heavy labeling of the glycine free N-
terminus (+146 dalton). The precursor mass tolerance is used to identify 
candidate peptides for MS/MS comparison from the FASTA database digested in 
silico. The fragment mass tolerance is the distance allowed between 
experimental and theoretical fragments to still be identified as a match. Relevant 
specific settings for the database search for LTQ-Velos Pro ion trap data were: 
precursor mass tolerance = 1.4 dalton, fragment mass tolerance = 0.8 dalton, 
and average masses were used. Relevant specific settings for the database 
search for LTQ-Velos Pro Orbitrap and Q-Exactive data were: precursor mass 
tolerance = 50 ppm, fragment mass tolerance = 1.0 dalton, and monoisotopic 
masses were used (these are the settings previously used by the Gygi and 
Harper groups for diGly remnant studies (158,159)). Protein inference challenges 
were resolved by applying parsimony rules; however assignment for protein 
families such as mouse myosins and actins were challenging given the high 
levels of redundancy of these protein families. For instance, myosin 4 was our 
top candidate for the myosin family peptide because all myosin family peptides 
matched to the myosin 4 sequence. Scaffold 4 (Proteome Software) was used in 
addition to Proteome Discoverer 1.4 for PSM viewing and figure preparation.  
	  Figure 15. Simplified MS/MS Spectrum. Simplified fragment ion spectra for 
(K)GADFLVTEVENGGSLGSK(K) peptide from Pyruvate kinase. The b-ion series (red) is displayed in (A) 
while the y-ion series is displayed in blue (B). 
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RESULTS 
1. Glycogen in MEFs from Mouse Models of Lafora Disease 
1.1. Preamble 
Lafora bodies are the hallmark of Lafora disease and in the different 
mouse models (32,81,108,109) of the disease, there is an over accumulation of 
abnormal hyperphosphorylated and poorly branched glycogen. Therefore, we 
analyzed the glycogen content in the MEFs derived from wild type (WT), Epm2a-
/- (LKO), Epm2b-/- (MKO) and Epm2a-/- Epm2b-/- (DKO) mice. The method 
used to determine glycogen levels in animal tissues (146) was adapted in order 
to measure the glycogen levels in mouse embryonic fibroblasts.  
 
1.2. Glycogen Levels in MEFs from Muscle Glycogen Synthase Gys1-/- 
Mice 
The Gys1-/- mice, which are deficient in the muscle isoform of glycogen 
synthase, were generated in our laboratory as previously described (160). We 
derived MEFs from Gys1-/- mice and their wild type littermates as described in 
section 2 of Experimental Procedures. This experiment was performed as a 
positive control to determine that the biochemical measurement of glycogen is in 
fact representative of the cellular condition. As seen in Figure 16, the glycogen 
content in the Gys1-/- MEFs was close to zero in comparison to the wild type 
controls. There is very little or no glycogen present in the Gys1-/- mice (161) and 
therefore the MEFs have similar phenotypes to the mouse with regard to 
	   63 
glycogen accumulation thus, validating the method for determination of glycogen 
in MEFs. 
 
1.3. Glycogen Levels in MEFs from Mouse Models of Lafora Disease 
Upon enzymatic digestion of glycogen by amyloglucosidase, both Epm2a-
/- and Epm2b-/- MEFs had ~50% more glycogen as compared to the wild type 
controls. The double Epm2a-/- Epm2b-/- MEFs, on the other hand, had 
unexpectedly less glycogen than even the wild type MEFs (Figure 17 A). It is 
possible that the distinct abnormal insoluble structure of glycogen in double 
Epm2a-/- Epm2b-/- MEFs could resist enzymatic degradation by 
amyloglucosidase and, therefore the partial/incomplete digestion of glycogen 
could give a lower value.  
In order to circumvent the problem, glycogen was hydrolyzed with HCl. 
Under these conditions, glycogen was ~70% higher in all the knockout cells as 
compared to the wild type control cells (Figure 17 B) similar to the results of 
tissues from the animal models (162). The double knockout cells showed the 
same increase as the single knockout consistent with the involvement of a similar 
pathway. 
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Figure 16. Glycogen in MEFs from Mice Lacking Muscle 
Glycogen Synthase. Glycogen levels in MEFs of wild type (WT) 
and Gys1-/- (MGSKO) mice were analyzed. The levels are 
expressed as glucose equivalents per mg protein. Values represent 
the average of three independent experiments ± SEM. Values 
marked by the same letter are not statistically significant, different 
letters indicate p<0.05. 
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Figure 17. Glycogen in MEFs from Mouse Models of Lafora 
Disease. Glycogen levels in MEFs of wild type (WT), Epm2a-/- 
(LKO), Epm2b-/- (MKO) and double Epm2a-/- Epm2b-/- (DKO) 
mice were analyzed. Glycogen was digested by A) 
amyloglucosidase or B) hydrochloric acid. The levels are expressed 
as glucose equivalents per mg protein. Values represent the 
average of three independent experiments ± SEM. Values marked 
by the same letter are not statistically significant, different letters 
indicate p<0.05. 
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2. Protein Quality Control Process in MEFs from Mouse Models Lafora 
Disease 
2.1. Preamble 
Protein quality control processes play a critical role in maintaining 
intracellular homeostasis. Misfolded proteins are either refolded with the help of 
cellular chaperones or are degraded via the ubiquitin-proteasomal pathway or the 
autophago-lysosomal pathway (163). The proteasome tends to clear short-lived 
proteins while long-lived proteins are degraded by autophagy. Proteins are 
ubiquitinated before being targeted for degradation. While degradation via the 
proteasome is specific to ubiquitinated proteins, autophagy involves bulk 
degradation of various proteins, lipid droplets, damaged organelles, which may 
cause cellular stress upon accumulation (164-166). Under conditions of stress 
due to accumulation of non-degradable material, the proteolytic machinery is 
saturated which results in formation of aggregates (167). Under normal 
conditions, a certain amount of protein misfolding occurs in the endoplasmic 
reticulum, ER, which is ameliorated by retrograde transport of the misfolded 
proteins into the cytosol for degradation via the proteasomal pathway. 
Impairment of the function of the proteasome can lead to induction of ER stress 
to enhance the protein folding capacity of the ER. Excessive and prolonged ER 
stress along with impaired proteasomal function results in accumulation and 
aggregation of unfolded proteins (168), eventually leading to cell death. 
We evaluated the three arms of the protein degradation/quality control 
process, the ubiquitin-proteasomal pathway, the autophago-lysosomal pathway 
	   67 
and the ER-stress response using primary embryonic fibroblasts (MEFs) derived 
from wild type, Epm2a-/-, Epm2b-/- and double Epm2a-/- Epm2b-/- mice. 
 
2.2. Proteasomal Activity in MEFs from Mouse Models of Lafora Disease 
Using MEFs from wild type (WT), Epm2a-/- (LKO), Epm2b-/- (MKO) and 
double Epm2a-/- Epm2b-/- (DKO) mice, the proteasomal function was assessed 
by measuring the chymotrypsin-like activity using the Suc-LLVY-aminoluciferin 
substrate. The absence of laforin and/or malin significantly decreased 
proteasomal activity in the knockout MEFs as compared to the wild type controls 
(Figure 18 A). However, the protein level of the S5a subunit of the 26S 
proteasome was not different between genotypes (Figure 18 B) suggesting that 
the observed difference in the chymotrypsin-like activity is not due to a difference 
in the levels of proteasome but rather intrinsic activity. Thus, proteasomal 
function is impaired in cells from mouse models of Lafora disease. 
 
2.3. Autophago-lysosomal Pathway in MEFs from Mouse Models of 
Lafora Disease 
Upon induction of autophagy, microtubule associated protein 1 light chain 
3 (LC3-I) is lipidated to LC3-II, which displays increased electrophoretic mobility. 
LC3-II is then incorporated into the inner and outer membranes of the newly 
formed autophagosomes, which fuse with the lysosomes to form autolysosomes 
where the engulfed components are degraded by the lysosomal enzymes (Figure 
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6). Thus, LC3-II is commonly used as a marker to evaluate autophagosome 
levels (169). 
MEFs were cultured in complete medium to assess basal autophagy or in 
serum-free and amino acid-free medium (EBSS) to induce autophagy by 
starvation (170). Under both basal and starved conditions, there was a significant 
decrease in the levels of LC3-II in knockout MEFs compared to the wild type 
controls (Figure 19 A, B). Starvation induced a significant increase in the LC3-II 
levels in the wild type cells but the effect was much smaller in the knockout cells. 
A decrease in the levels of LC3-II could either be due to impairment in the 
formation of autophagosomes or an increase in the degradation by 
autolysosomes. To differentiate between the two, MEFs were treated with 20 µM 
chloroquine, a lysosomal inhibitor, for 2 hours to block the degradation of LC3-II. 
The changes in the levels of LC3-II upon lysosomal inhibition should, thus, reflect 
changes in the rate of formation of autophagosomes (169). In the presence of 
chloroquine, there was still a significant decrease in the levels of LC3-II in 
knockout MEFs indicating impairment in the formation of autophagosomes 
(Figure 19 C, D). Combined starvation and chloroquine treatment still resulted in 
a small increase in the levels of LC3-II even in knockout MEFs but the increase 
was significantly lower than in the wild type MEFs (Figure 19 C, D). This small 
increase was further decreased in the double knockout cells. Thus, the absence 
of either laforin or malin dampens the autophagic process. 
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Figure 18. Proteasomal Activity in MEFs from Mouse Models of 
Lafora Disease. Soluble extracts derived from MEFs of wild type 
(WT), Epm2a-/- (LKO), Epm2b-/- (MKO) and double Epm2a-/- 
Epm2b-/- (DKO) mice were analyzed. A) Proteasomal activities 
were measured in soluble lysates (10 µg) using Proteasome-Glo™ 
Chymotrypsin-like assay. Values represent the average of three 
independent experiments performed in duplicates ± SEM. RLU-
relative luminescence unit. Values marked by the same letter are 
not statistically significant, different letters indicate p<0.05. B) 
Representative Western blots using antibody against S5a subunit 
of the 26S proteasome. Loadings were 10 µg of protein. GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. 
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Figure 19. Autophagy in MEFs from Mouse Models of Lafora 
Disease. MEFs from wild-type (WT), Epm2a-/- (LKO), Epm2b-/- 
(MKO) and double Epm2a-/- Epm2b-/- (DKO) mice were incubated 
without and with 20 µM chloroquine for 2 hours under basal (NS) or 
starvation (S) conditions. Total lysates (10 µg) from MEFs were 
analyzed. A, C) Representative Western blots using antibody 
against LC3 in the absence and presence of chloroquine, 
respectively. The positions of LC3-I and LC3-II are indicated on the 
left. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B, D) 
LC3-II bands were quantitated by densitometry and normalized to 
the corresponding GAPDH bands. Values represent the average of 
three independent experiments ± SEM. Values marked by the 
same letter are not statistically significant, different letters indicate 
p<0.05. 
 
 
	  
	   71 
2.4. mTOR Signaling Pathway in MEFs from Mouse Models of Lafora 
Disease 
mTOR, mammalian target of rapamycin, negatively regulates autophagy. 
Nutritional deprivation inhibits mTOR and thus induces autophagy. Conversely, 
nutrient replenishment activates mTOR and suppresses autophagy (171,172). 
Activation of mTOR causes phosphorylation of downstream targets such as 
ribosomal protein S6 kinase (p70S6K) and its substrate ribosomal protein S6. 
Analysis of the levels of phosphorylated p70S6K and S6 protein indicated 
increased phosphorylation (Figure 20 A, B and Figure 20 A) under basal 
conditions in the knockout MEFs. Upon starvation, although there was a 
decrease in the phosphorylation of the S6 protein compared to the basal state, 
the phosphorylation in knockout MEFs was still higher than in the wild type 
control cells (Figure 20 B and Figure 21 A, high exposure). When MEFs were 
treated with 10 nM of rapamycin for 2 hours, the level of phosphorylated S6 
protein in all MEFs decreased significantly as compared to the basal levels 
(Figure 21 A). Taken together, these observations suggest that mTOR signaling 
is upregulated in knockout cells and impairment of autophagy may be mTOR 
dependent. 
Consistent with inhibition of mTOR, upon rapamycin treatment, LC3-II was 
increased in the wild type cells to a level similar to that of starvation. LC3-II in the 
knockout MEFs was also increased to the same level in the starved and 
rapamycin treated cells, although the effect did not reach the levels of the wild 
type cells (Figure 21 B, C). These observations suggest that either the autophagy 
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defect in knockout MEFs is only partly mTOR-dependent or that the maximum 
capacity of the cells to form new autophagosomes is impaired in the absence of 
laforin and/or malin. 
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Figure 20. mTOR Signaling Pathway in MEFs from Mouse 
Models of Lafora Disease. MEFs from wild-type (WT), Epm2a-/- 
(LKO), Epm2b-/- (MKO) and double Epm2a-/- Epm2b-/- (DKO) 
mice were incubated under basal (NS) or starvation (S) conditions 
for 2 hours. Soluble extracts (10 µg) from MEFs were analyzed. 
Representative Western blots are shown against different 
antibodies; A) phosphorylated Thr389 p70S6 kinase and total S6K, 
B) phosphorylated Ser235/236S6 and total S6 protein. GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. C, D) P-S6K and P-
S6 bands were quantified by densitometry and normalized to the 
corresponding total S6K and total S6 bands, respectively. Values 
represent the average of three independent experiments ± SEM. 
Values marked by the same letter are not statistically significant, 
different letters indicate p<0.05. 
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Figure 21. mTOR Signaling Pathway upon Rapamycin 
Treatment in MEFs from Mouse Models of Lafora Disease. 
MEFs from wild-type (WT), Epm2a-/- (LKO), Epm2b-/- (MKO) and 
double Epm2a-/- Epm2b-/- (DKO) mice were incubated under basal 
(NS) or starvation (S) conditions or with 10 nM rapamycin (Ra) for 2 
hours. Soluble extracts (10 µg) from MEFs were analyzed. 
Representative Western blots are shown against different 
antibodies; A) phosphorylated Ser235/236S6 and total S6 protein, B) 
LC3. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. C) 
LC3-II bands were quantified by densitometry and normalized to 
the corresponding GAPDH bands. Values represent the average of 
three independent experiments ± SEM. Values marked by the 
same letter are not statistically significant, different letters indicate 
p<0.05. 
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2.5. . Effect of Malin Deficiency on Lysosome and Late Endosome 
Markers 
LC3 belongs to the autophagy-related genes 8 (Atg8) family, which 
includes γ-amino butyric acid receptor-associated protein-like 1 (GABARAPL1). 
Starch-binding domain protein 1 (Stbd1 or genethonin 1), a membrane and 
glycogen-binding protein, has been shown to interact with GABARAPL1 and 
abnormal glycogen and might be involved in the transfer of abnormal glycogen to 
lysosomes (33,60). We observed no difference in Stbd1 protein in the knockout 
MEFs as compared to the wild type controls (Figure 22 A). We also analyzed the 
levels of GABARAPL1 and interestingly, the levels of GABARAPL1 in the LKO 
MEFs were similar to the wild type controls whereas GABARAPL1 was much 
lower in MKO cells as compared to the wild type or to the LKO cells (Figure 22 A, 
B). Similar to GABARAPL1, LAMP1, a marker of late endosomes and lysosomes, 
was unchanged in LKO but significantly lower in the MKO cells (Figure 22 A, C). 
Additional loss of laforin in the DKO cells did not cause any further decrease in 
either GABARAPL1 or LAMP1 levels (Figure 22 A). These results suggest that 
there may not be a complete overlap in the functions of malin and laforin, as 
proposed by previous studies (115,125,127), and that a unique function of malin 
might be related to lysosome biogenesis or lysosomal trafficking of glycogen. 
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Figure 22. Lysosome and Late Endosome Markers in MEFs 
from Mouse Models of Lafora Disease. MEFs from wild-type 
(WT), Epm2a-/- (LKO), Epm2b-/- (MKO) and double Epm2a-/- 
Epm2b-/- (DKO) mice were incubated under basal conditions (NS) 
or starvation (S) for 2 hours. Total lysates (10 µg) from MEFs were 
analyzed. Representative Western blots using antibodies against A) 
GABARAPL1, LAMP1 and Stbd1. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. B, C) GABARAPL1 or LAMP1 bands 
were quantified by densitometry and normalized to the 
corresponding GAPDH bands. Values represent the average of 
three independent experiments ± SEM. Values marked by the 
same letter are not statistically significant, different letters indicate 
p<0.05. 
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2.6. Degradation of Ubiquitinated Proteins in Laforin and/or Malin 
Deficient Cells 
Ubiquitinated proteins are degraded either via the ubiquitin-proteasomal or 
the autophago-lysosomal pathway depending on the lysine involved in the 
formation of the polyubiquitinated chains (122,124). We compared the levels of 
ubiquitinated proteins in the knockout MEFs with the wild type controls. Under 
basal conditions, there was no difference in the level of ubiquitinated proteins. 
However, upon starvation, there was a significant decrease in ubiquitinated 
proteins in wild type cells while in the knockout MEFs the levels were no different 
than the basal state (Figure 23 A, D). When the MEFs were treated with the 
lysosomal inhibitor chloroquine (Figure 23 B, E) or the proteasomal inhibitor 
MG132 (Figure 23 C, F), even under starvation conditions, neither the wild type 
nor the knockout MEFs showed any decrease in levels of ubiquitinated proteins. 
These results indicate that loss of laforin and/or malin impairs the starvation- or 
stress-induced degradation of the ubiquitinated proteins and that the degradation 
could be either via the ubiquitin-proteasomal or the autophago-lysosomal 
pathway. 
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Figure 23. Degradation of Ubiquitinated Proteins in MEFs from 
Mouse Models of Lafora Disease. MEFs from wild-type (WT), 
Epm2a-/- (LKO), Epm2b-/- (MKO) and double Epm2a-/- Epm2b-/- 
(DKO) mice were incubated under basal conditions (NS) or 
starvation (S) without or with 20 µM chloroquine or 20 µM MG132 
for 2 hours. Soluble extracts (10 µg) from MEFs were analyzed. 
Representative Western blots using anti-ubiquitin antibody against 
ubiquitinated proteins A) without and B) with chloroquine or C) with 
MG132. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. D, 
E, F) Bands for ubiquitinated proteins were quantified by 
densitometry and normalized to the corresponding GAPDH bands. 
Values represent the average of three independent experiments ± 
SEM. Values marked by the same letter are not statistically 
significant, different letters indicate p<0.05. 
 
	  
	   79 
2.7. ER Stress Response in MEFs from Mouse Models of Lafora Disease 
Impairment of proteasomal function might lead to induction at the 
endoplasmic reticulum, ER stress. An earlier study by Vernia et al. (135) 
suggested that laforin deficiency leads to an increased sensitivity to ER stress-
inducing agents. Therefore, we investigated the third arm of protein quality 
control, the ER stress response in MEFs by analyzing the expression of the 
transcriptional factor CHOP (173), a widely used ER stress marker. MEFs were 
treated with two known ER stress-inducing agents, thapsigargin, an inhibitor of 
the ER calcium pump and tunicamycin, an inhibitor of ER glycosylation. The 
levels of CHOP were higher upon treatment with thapsigargin or tunicamycin by 
comparison to the basal condition both in wild type and in the knockout MEFs 
with no differences between genotypes (Figure 24 A, B). Thus, the ER stress 
response is not compromised in the absence of malin and/or laforin. 
 
	   80 
 
Figure 24. ER Stress Response in MEFs from Mouse Models of 
Lafora Disease. MEFs from wild-type (WT), Epm2a-/- (LKO), 
Epm2b-/- (MKO) and double Epm2a-/- Epm2b-/- (DKO) mice were 
incubated without or with 1 µM thapsigargin or 2 µg/ml tunicamycin 
for 18 hours. Soluble extracts (10 µg) from MEFs were analyzed. A) 
Representative Western blots using antibody against CHOP. 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B) Bands 
for CHOP were quantified by densitometry and normalized to the 
corresponding GAPDH bands. Values represent the average of 
three independent experiments ± SEM. Values marked by the 
same letter are not statistically significant, different letters indicate 
p<0.05. 
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3. Malin-dependent Ubiquitylome in Lafora Disease 
3.1. Preamble 
Malin contains a RING finger domain characteristic of an E3 ubiquitin 
ligase (81). A number of different studies have attempted to identify the 
substrates of malin and several proteins involved in glycogen metabolism, laforin 
(101), glycogen synthase (115), protein targeted to glycogen (PTG) (127) and the 
debranching enzyme (AGL) (125) have been proposed to be malin substrates. 
However, most of these conclusions are based on either in vitro or cell culture 
overexpression systems. Moreover, results in our laboratory with Epm2b-/- mice 
did not provide any evidence for alterations in levels of PTG and AGL or in 
glycogen synthase activity (108) arguing against them being malin substrates. 
In this study, we present the development of an unbiased proteomics 
approach to identify potential substrates of malin. Ubiquitination of proteins 
involves a chain of three reactions as described in section 7.4 of the Introduction 
(Figure 11). An isopeptide bond is formed between the C-terminal glycine and 
the ε-amino group of the lysine residue in the substrate. Trypsinolysis of proteins 
cleaves the C-terminal Arg-Gly-Gly sequence of ubiquitin and yields a 
characteristic diGly remnant on the lysine of the substrate (Figure 25). The diGly 
remnant provides a method for detection of ubiquitinated peptides by mass 
spectrometry. The approach was developed to systematically identify malin-
dependent ubiquitination targets using quantitative diGly proteomics. This 
involved anti-diGly antibody-based capture of diGly ubiquitin-remnant containing 
peptides (158) from wild type and Epm2b-/- mice (Figure 26), that are 
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differentially labeled. In the absence of malin in the Epm2b-/- mice, the potential 
malin substrate might not be ubiquitinated and the absence of the peptide from 
Epm2b-/- lysates on mass spectrometry would identify candidate malin 
substrates. 
 
Figure 25. Ubiquitination reaction. An isopeptide bond is formed 
between C-terminal glycine and the ε-amino group of the lysine 
residue in the protein. Trypsinolysis of the proteins cleaves the Arg-
Gly-Gly sequence of ubiquitin and yields a Gly-Gly remnant on the 
lysine of the protein. 
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Figure 26. Quantitative diGly Proteomics Approach. It involves 
anti-diGly antibody-based capture of the diGly ubiquitin remnant 
containing differentially labeled peptides from wild type and Epm2b-
/- mice. 
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3.2. Quantitative diGly Proteomics using SILAC 
To investigate the ubiquitin proteome, MEFs derived from wild type and 
Epm2b-/- mice were cultured in lysine and arginine-free medium supplemented 
with either [12C614N2] lysine (K0) and [12C614N4] arginine (R0) (light medium) or 
[13C615N2] lysine (K8) and [13C615N4] arginine (R10) (heavy medium). Proteolysis 
by Lys-C and trypsin generated diGly remnants on the lysine on the peptides. In 
the absence of malin, the potential substrate might not be ubiquitinated and 
might not be immunoprecipitated by the diGly antibody and therefore not 
detected by mass spectrometry (Figure 27). 
The cells (twelve 150 mm culture plates for each genotype) were 
incubated in either light or heavy medium that contained 20 µM MG132 for four 
hours before the time of harvest. MG132 should prevent the degradation of the 
substrate in the wild type cells by blocking the proteasomal activity. The cells 
were harvested and lysates were prepared as described in section 14.1 of 
Experimental Procedures. The lysates from the light and heavy cells were mixed 
in a 1:1 ratio based on protein concentration and then digested overnight with 
Lys-C followed by overnight digestion with Trypsin-Gold. The digestion was 
quenched by addition of 20% TFA to a final concentration of 1%. The acidified 
peptides were purified using a C 18 Sep-Pak column and then lyophilized for 3 
days. The lyophilized peptides were then immunoaffinity-purified using the diGly 
antibody, concentrated using C18 StageTips followed by mass spectrometry. 
 
	   
Figure 27. Quantitative diGly proteomics using SILAC. MEFs from wild type and Epm2b-/- mice were 
cultured in medium containing heavy and light amino acids, respectively. The cells were lysed and mixed in 
1:1 ratio followed by proteolysis by Lys-C and trypsin yielding diGly remnants, which were 
immunoprecipitated using anti-diGly antibody. The final eluate from the immunoprecipitation is analyzed by 
mass spectrometry. 
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3.2.1. Serum Contaminants in Cell Lysates 
The presence of serum proteins, in particular bovine albumin, interfered 
with the detection of the murine peptides. Albumin was present at levels much 
higher than the most abundant murine peptide, vimentin (Table 1). It is difficult to 
avoid contamination by albumin because it adheres not only to the cells in culture 
but also to the cell culture plates (174). Table 1 shows the list of the top 12 
proteins obtained from MudPIT-LC/MS analysis. About 50% of the proteins were 
of bovine origin. Furthermore, there is a considerable homology between proteins 
from Bos taurus and Mus musculus; for example, myosin 9 from Mus musculus 
had homology to myosin 10 from Bos taurus. This makes it difficult to distinguish 
between bovine and murine peptides because of the overlap of identical tryptic 
peptide sequences. Subsequent experiments were focused on removal of serum 
contaminating proteins, mainly albumin, at the time of harvest and cell lysis. 
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Table 1. diGly Proteomics using SILAC. Proteins identified by 
quantitative diGly proteomics approach using SILAC in MEFs 
derived from wild type and Epm2b-/- mice. 
 
Description Source Coverage #Peptides #PSMs MW   
Albumin Bos 
taurus 
54.86 26 247 69.2 
Alpha-1-
antiproteinase 
Precursor 
Bos 
taurus 
24.52 8 77 46.1 
Alpha-2-HS-
glycoprotein 
precursor 
Bos 
taurus 
31.75 9 66 38.4 
Vimentin Mus 
musculus 
33.69 12 56 53.7 
Myosin-9 Mus 
musculus 
11.12 16 49 226.2 
Serotransferrin 
precursor 
Bos 
taurus 
31.39 15 38 77.7 
Serum albumin 
precursor 
Mus 
musculus 
4.77 2 33 68.6 
Actin, 
cytoplasmic 2 
Bos 
taurus 
40.80 10 31 41.8 
Tubulin alpha-1B 
chain 
Bos 
taurus 
20.40 6 31 50.1 
Alpha acitinin-1 Mus 
musculus 
14.13 10 26 103.0 
Myosin-10 Bos 
taurus 
6.43 9 26 229.0 
Prelamin-A/C 
isoform A 
Mus 
musculus 
18.35 10 25 74.2 
Coverage: The percentage of amino acid sequence identified by 
matching tryptic peptides 
# PSMs: The number of peptide spectral matches 
#Peptides: The number of peptides that were detected 
MW: The molecular weight of protein in kilodaltons 
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3.2.2. Modified Washing Techniques to Avoid Albumin 
Contamination 
At the time of harvest, the culture medium was removed by aspiration and 
the cells were washed three times with 10 ml of ice cold PBS. The washes were 
modified to three 5-minute washes with PBS on an orbital shaker at 4oC or three 
5-minute washes with serum-free medium on an orbital shaker at 4oC or three 5-
minute washes of cells in suspension with PBS as described in section 8 of 
Experimental Procedures. Figure 28 shows that the cross contamination with 
albumin was present even after extended washes with PBS or serum-free 
medium. 
 
3.2.3. Culturing Cells in Serum-free Medium (SFM) 
Since it was difficult to remove albumin by extended washes, we tried to culture 
the cells in serum-free conditions. The FibroGRO™ Complete Media Kit from 
Millipore was used as an alternative to DMEM:F12 medium with 10% FBS. The 
cells were adapted to grow in the serum-free media (SFM) either by direct 
adaptation or by sequential adaptation as described in section 6 of Experimental 
Procedures. The cells failed to survive after direct adaptation from full medium to 
SFM. Therefore, the cells were cultured by sequential adaptation that involved 
serial switching to medium with different ratios of Full medium:SFM: 100:0, 
70:30, 50:50, 30:70, 20:80 and 0:100. Figure 29 A represents the cell 
morphology at each step. There was no change in the morphology of the cells till 
a 50:50 ratio of Full:SFM. At a 30:70 ratio, there was a change in the morphology 
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of the cells with a lower number of cells surviving after each passage. There was 
a significant increase in the number of cells with altered morphology and 
increased cell death at 20:80 ratio of Full:SFM (Figure 29 A). 
 
Figure 28. Modified Washing Techniques for Removal of 
Albumin. After removing the medium, cells were washed by four 
different methods. 1. Three washes with PBS, 2. Extended washes 
with PBS, 3. Washes in suspension after trypsinization and 4. 
Extended washes with serum-free medium. Soluble extracts (20 
µg) from the cells were analyzed. A) Representative western blot 
using antibody against BSA. BSA, bovine serum albumin; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase. B) SDS-PAGE 
analysis with Coomassie staining showing BSA. 
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3.2.4. Culturing Cells in Low Serum Medium 
While growing in SFM, the cells could maintain normal morphology only 
up to a Full:SFM ratio of 30:70. Since the cells failed to survive in the absence of 
serum, we tried to culture the cells under low-serum conditions. The cells were 
initially cultured with 10% serum and then switched to medium with reduced 
serum as described in section 7 of the Experimental Procedures. The cells were 
able to survive with 2% serum without a change in morphology; however at 1% 
serum the majority of the cells either failed to grow or had altered morphology 
(Figure 29 B). The antibiotics used in culture tend to bind to various serum 
proteins, thus reducing the effective concentration of the antibiotics (175). 
Therefore, in low serum medium, the concentration of antibiotics was reduced to 
avoid cell death due to antibiotic toxicity. The cells were cultured in DMEM-F12 
with 2% dialyzed FBS and reduced antibiotic concentrations (20 units/ml of 
penicillin and 20 µg/ml of streptomycin) for SILAC. The cell lysate was analyzed 
by mass spectrometry for the presence of contaminant serum proteins. Table 2 
lists the most abundant proteins obtained from MudPIT-LC/MS analysis. In 
contrast to Table 1, the majority of the proteins in Table 2 are of murine origin. 
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Figure 29. Cell Culture in Serum-free and Low Serum 
Conditions. A) Cells were cultured in full medium (a) and then 
sequentially adapted from Full:SFM ratio of 70:30 to 20:80 (b-e). B) 
Cells were cultured in full medium that contained 10% FBS (a) or 
2% FBS (b) or 1% FBS (c). SFM, serum-free medium; FBS, fetal 
bovine serum. All pictures were taken using a stereoscopic 
microscope (Nikon Corporation). 
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Table 2. diGly Proteomics using SILAC with Low Serum 
Medium. Proteins identified by quantitative diGly proteomics 
approach using SILAC in MEFs derived from wild type and Epm2b-
/- mice cultured in medium with 2% serum. 
 
Description Source Coverage #Peptides #PSMs 
Fibronectin Mus 
musculus 
29.79 48 1027 
Actin Mus 
musculus 
38.40 12 613 
Vimentin Mus 
musculus 
52.58 21 515 
Fibulin-2 isoform b Mus 
musculus 
28.36 23 494 
Myosin-9 isoform 1 Mus 
musculus 
35.77 61 403 
Vimentin Bos 
Taurus 
38.63 16 333 
Actin, alpha cardiac 
muscle 1 
Mus 
musculus 
45.89 13 325 
Galectin-1 Mus 
musculus 
31.85 3 295 
Tubulin beta-5 
chain 
Mus 
musculus 
27.25 10 286 
Tubulin alpha-1 B 
chain 
Mus 
musculus 
29.71 9 274 
Coverage: The percentage of amino acid sequence identified by 
matching tryptic peptides 
# PSMs: The number of peptide spectral matches 
#Peptides: The number of peptides that were detected 
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3.2.5. Difficulties in SILAC Labeling and Cell Culture 
The labeling of MEFs with heavy lysine and arginine was very poor. Even 
after culturing the cells in heavy medium for 4-6 weeks, close to 100% labeling 
efficiency could not be obtained as verified by mass spectrometric analysis. 
Figure 30 represents a MS/MS spectrum for the tryptic peptide 
KGVNLPGAAVDLPAVSEK, which contains an N-terminal lysine, a possible 
missed cleavage site, even after proteolysis by trypsin. The C-terminal lysine of 
the tryptic peptide is heavy whereas the N-terminal lysine is light, thus 
representing an incomplete labeling with heavy amino acids. Moreover, to obtain 
higher starting amounts of protein from cells, at least 20-150 mm cell culture 
plates were needed. It was difficult to culture cells in 2% FBS to obtain higher 
number since the cell growth was slower as compared to 10% FBS. 
 
	   
Figure 30. MS/MS Spectrum Showing Incomplete Labeling. MS/MS spectrum for the tryptic peptide 
KGVNLPGAAVDLPAVSEK showing a pattern for incomplete labeling. Lower case lysine is heavy. 
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3.3. Ubiquitin Proteome of Mouse Skeletal Muscle using Quantitative 
diGly Proteomics 
Since identification of ubiquitinated proteins by SILAC in MEFs was not 
achievable, we used mouse skeletal muscle instead, utilizing a similar diGly 
proteomics approach. Around 800 mg of frozen mouse skeletal muscle from 6 
month-old wild type male mice was used. Around 150 mg of protein was 
obtained, which was digested overnight by trypsin after reduction and alkylation 
of the cysteines. The diGly peptides generated after trypsin digestion were 
immunoprecipitated using anti-diGly antibody and then analyzed by mass 
spectrometry (Figure 31), which resulted in identification of ubiquitinated 
peptides. Technical replicates of the sample were analyzed and the data were 
pooled together for the analysis. In total, 244 non-redundant ubiquitination sites 
were detected in 182 proteins following combination of all MudPIT-LC/MS 
analyses. The 25 most abundant proteins identified based on the peptide 
spectral match (PSM) are shown in Table 3. A PSM is a match between an 
observed peptide spectrum and the theoretical peptide spectrum in the database. 
In our experiments, we record the total number of PSMs by which a particular 
peptide is identified over a course of a MudPIT by the mass spectrometer and 
matched with the database. For example, in Table 3, Myh4 was detected 26093 
times (PSM 26093) as compared to Ube2n, which was detected 24 times (PSM 
24). 
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Figure 31. Approach for diGly Proteomics in Mouse Skeletal 
Muscle. Tissue lysate prepared from mouse skeletal muscle was 
digested by trypsin to yield peptides that contain diGly remnant. 
These peptides were immunoprecipitated using anti-diGly antibody 
and analyzed by mass spectrometry. 
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Table 3. Mouse Ubiquitylome using diGly Proteomics 
Approach. 25 most abundant proteins from mouse skeletal muscle 
identified with ubiquitinated peptides following diGly immunoaffinity 
purification and MudPIT-LC/MS analysis. 
 
Accession Description Coverage #PSMs MW 
Q5SX39 Myosin heavy chain 4 66.99 26093 222.7 
Q5SX40 Myosin heavy chain 1 60.30 17222 223.2 
P13542 Myosin heavy chain 8 47.81 12666 222.6 
G3UW82 Myosin heavy chain 2 59.53 12580 223.1 
P68134 Alpha-actin 1 58.09 9126 42 
P62737 Alpha-actin 2 57.82 8976 42 
P13541 Myosin heavy chain 3 26.19 7401 223.7 
Q91Z83 Myosin heavy chain 7 37.31 6629 222.7 
Q02566 Myosin heavy chain 6 31.68 6311 223.4 
P07310 Creatine kinase M-type 49.08 5697 39.3 
B1AR69 Myosin heavy chain 13 23.07 4949 223.4 
P97457 Myosin regulatory light chain 2 92.31 2120 18.9 
P60710 Actin 2 41.67 2602 11.4 
P05977 Myosin light chain 1 63.83 2094 20.6 
P05064 Fructose-bisphosphate 
aldolase A 
47.53 1916 39.3 
A6Z147 Fructose-bisphosphate 
aldolase 
22.80 1158 39.3 
P20801 Troponin C 22.50 619 18.1 
P11404 Fatty acid-binding protein, 
heart 
39.10 186 14.8 
F8WIX8 Histone H2A 28.80 90 13.6 
D3YYZ2 Uncharacterized protein 46.72 58 14.1 
E9Q6Z0 Cullin 5 3.38 28 75.9 
Q497M3 Putative C->-U-editing enzyme 
APOBEC-4 
4.01 24 42.7 
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Accession: The unique accession number for protein in UniProtKB 
Coverage: The percentage of amino acid sequence identified by 
matching tryptic peptides 
# PSMs: The number of peptide spectral matches 
#Peptides: The number of peptides that were detected 
MW: The molecular weight of protein in kilodaltons  
 
 
Histone H2A is one of the five histones involved in the structure of 
chromatin in cells (176). H2A has been shown to be monoubquitinated at lysine 
119 (K119) to regulate target genes (177) As a validation of the approach, H2A 
was identified with a diGly remnant present at lysine 119 (K119). Figure 32 
represents the MS/MS spectrum of the ubiquitinated tryptic peptide 
VTIAQGGVLPNIQAVLLPKK identified in our studies for Histone H2A. 
  
Accession Description Coverage #PSMs MW 
P70295 Ancient ubiquitous protein 1 3.66 21 46.1 
Q02053 Ubiquitin-activating enzyme 1 5.10 17 117.7 
P61089 Ubiquitin-conjugating enzyme 
E2 N 
36.18 24 17.1 
	   
Figure 32. MS/MS Spectrum of Histone H2A. A) Sequence of tryptic peptide containing the site of 
ubiquitintation (GlyGly). B) MS/MS spectrum obtained from the tryptic peptide VTIAQGGVLPNIQAVLLPKK. 
The y-ion series is shown in blue while the b-ion series is shown in red. 
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Myosin-4, the top hit from the analysis, had nine distinct ubiquitination 
sites. Figure 33 shows the sequence coverage for myosin-4. With an overall 
coverage of 46% (894 amino acids out of 1939), we detected a total of 4715 
spectra, 27 exclusive unique peptides and 65 exclusive unique spectra for 
myosin-4. Figure 34 (A-I) shows the MS/MS spectra for myosin-4 for all the nine 
ubiquitination sites identified after diGly immunoaffinity purification. Out of the 
nine, four modified sites were identified in redundant peptides found in other 
myosin family members. In brief, the potential sites that could be ubiquitinated in 
other myosin isoforms include: lysine 1902 (exact peptide also found in myosin-
1), lysine 1809 (exact peptide also found in myosin 1, 2, 3, 6, 7, 8 and 13), lysine 
1922 (exact peptide also found in myosin 1, 3, 6, 7, 8 and 13) and lysine 453 
(exact peptide also found in myosin 1, 2, 8 and 13). 
 
	  Figure 33. Myosin-4 Sequence Coverage. Schematic representation of myosin-4 with sequence coverage 
indicated in yellow; the modified residues (including methylation labeling, methionine oxidation and diGly) 
are indicated in green. A total of 4715 total spectra were detected with 46% coverage, 27 exclusive unique 
peptides and 65 exclusive unique spectra. 
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Figure 34. MS/MS Spectra for Myosin-4. MS/MS spectra obtained 
after diGly immunoaffinity purification from tryptic peptides of 
modified lysine in myosin-4 A) Lysine 1476; B) Lysine 1448; C) 
Lysine 44; D) Lysine 73; E) Lysine 64; F) Lysine 1902; G) Lysine 
1809; H) Lysine 1922 and I) Lysine 453. The modified residues are 
represented in lower case. The y-ion series is shown in blue while 
the b-ion series is shown in red. 
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Technical replicates of the sample were analyzed on a LTQ Velos Pro ion 
trap or a Q-Exactive mass spectrometer. Data were collected for MS/MS analysis 
following collision-induced dissociation  (CID) or higher-energy collision-induced 
dissociation (HCD) fragmentation. Figure 35 and Figure 36 show a comparison 
between the CID and HCD fragmentation pattern of peptides. There is much 
lower b ion fragmentation coverage in HCD in comparison to CID. Compared to 
CID, HCD fragmentation has high resolution precursor ion detection set at 
resolution of 70,000 for these experiments (178) and therefore we used it to 
confirm the sites of diGly modification obtained from CID fragmentation. 
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Figure 35. MS/MS Spectra for Myosin-4: HCD vs. CID. 
Comparison of MS/MS spectra after HCD and CID fragmentation 
for peptide SSVFVVDAkESYVK obtained from myosin 4 after diGly 
immunoaffinity purification. The y-ion series is shown in blue while 
the b-ion series is shown in red. QE; Q-Exactive, VP; Velos Pro. 
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Figure 36. MS/MS Spectra for Histone H2A: HCD vs. CID. 
Comparison of MS/MS spectra after HCD and CID fragmentation 
for peptide VTIAQGGVLPNIQAVLLPkK obtained from histone H2A 
after diGly immunoaffinity purification. The y-ion series is shown in 
blue while the b-ion series is shown in red. QE; Q-Exactive, VP; 
Velos Pro. 
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An unbiased approach was used for functional annotation by using the 
database for annotation, visualization and integrated discovery (DAVID), which 
was developed by Huang et al. (179). The DAVID bioinformatics database was 
queried using the 25 most abundant proteins that were obtained from MudPIT 
LC/MS analysis in Table 3. The top 25 proteins’ dataset organized into 
biofunctional categories can be seen in Figure 37. Biofunctions with (-log p-
values) from this analysis (Table 4) are represented in Figure 38. The 
ubiquitinated proteins could either be substrates that undergo ubiquitination as a 
post-translational modification for regulation of function or substrates of the 
quality control process and protein turnover. Data analysis by DAVID (Figure 37) 
highlights that the majority of the ubiquitinated proteins are cytoskeletal or motor 
proteins primarily involved in muscle function. Small groups of proteins were 
predicted to be involved in development of muscle and cellular or catabolic 
processes. 
	  Figure 37. Biofunctional Categories in Mouse Ubiquitylome. Using DAVID, biofunctional categorization 
was performed for 25 most abundant proteins from mouse skeletal muscle identified with ubiquitination 
peptides following diGly immunoaffinity purification and MudPIT LC/MS analysis. 
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Table 4. Functional Annotation for Mouse Ubiquitylome. Using 
DAVID, functional annotation was performed for 25 most abundant 
proteins from mouse skeletal muscle identified with ubiquitination 
peptides following diGly immunoaffinity purification and MudPIT 
LC/MS analysis. 
 
Annotation Cluster 1 p-value -log(p-value) 
Enrichment Score: 13.63   
Motor Activity 7.6E-12 11.12 
Annotation Cluster 2 p-value -log(p-value) 
Enrichment Score: 10.42   
Heavy chain of Myosin 2.5E-17 16.60 
Myosin filament 2.8E-15 14.55 
Myosin tail 2.7E-15 14.57 
Myosin head, motor region 2.4E-12 11.62 
Annotation Cluster 3 p-value -log(p-value) 
Enrichment Score: 9.28   
Actin-binding 4.1E-11 10.39 
Actin filament binding 6.2E-9 8.21 
Annotation Cluster 4 p-value -log(p-value) 
Enrichment Score: 7.43   
Non-membrane-bounded organelle 2.5E-7 6.60 
Intracellular non-membrane-bounded organelle 2.5E-7 6.60 
Annotation Cluster 5 p-value -log(p-value) 
Enrichment Score: 6.81   
ATP-binding 1.4E-9 8.85 
Nucleotide-binding 2.0E-8 7.70 
Nucleoside-binding 1.5E-7 6.82 
Annotation Cluster 6 p-value -log(p-value) 
Enrichment Score: 3.29   
Striated muscle development 9.5E-3 2.02 
Muscle tissue development 1.1E-2 1.96 
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Muscle organ development 1.8E-2 1.74 
Annotation Cluster 7 p-value -log(p-value) 
Enrichment Score:1.7    
Domain: EF hand 3 3.8E-3 2.42 
Calcium-binding EF-hand 1.0E-2 2.00 
Annotation Cluster 8 p-value -log(p-value) 
Enrichment Score:0.83   
Ubl conjugation pathway 1.0E-1 1.00 
Modification-dependent protein catabolic 
process 
1.2E-1 0.92 
Protein catabolic process 1.4E-1 0.85 
Proteolysis 3.5E-1 0.46 
Annotation cluster: A group of terms having similar biological 
meaning due to sharing similar gene members. 
Enrichment score: The overall enrichment score for the group 
based on the EASE scores of each term members; the higher, the 
more enriched. 
p-value: Modified Fisher Exact p-value or the EASE score; the 
smaller, the more enriched. 
-log(p-value): Calculated negative logarithm of the p-value 
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Figure 38. Functional Annotation for Mouse Ubiquitylome. 
Using DAVID, functional annotation was performed for 25 most 
abundant proteins from mouse skeletal muscle identified with 
ubiquitination peptides following diGly immunoaffinity purification 
and MudPIT LC/MS analysis. 
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3.4. Differential Labeling of Mouse Skeletal Muscle by Stable Isotope 
Dimethyl Labeling 
In order to perform a comparative and quantitative ubiquitin-proteomic 
study, a differential isotopic labeling approach was developed using stable 
isotope dimethyl labeling. Dimethyl labeling, first described by Hsu et al. (180), is 
based on a reaction between primary amines of a peptide (the N-terminus or an 
ε-amino group of a lysine residue) and formaldehyde to form a Schiff base that is 
reduced by sodium cyanoborohydride to form a dimethylamino group. Use of 
regular formaldehyde and sodium cyanoborohydride generates a mass increase 
of 28 Da per primary amine on the peptide (light), while deuterated formaldehyde 
and sodium cyanoborohydride generates a mass increase of 32 Da per primary 
amine (heavy) (Figure 39). Differential labeling of the proteins enables 
simultaneous quantitative LC-MS analysis of different samples. Labeling of the 
tryptic peptides with the aforementioned method generates peptides with a mass 
difference of either 4 Da (cleaved after an arginine residue) or 8 Da (when 
cleaved after a lysine residue) between the light and heavy label. If this peptide is 
also ubiquitinated at an internal lysine residue, an additional mass difference of 4 
Da will be observed due to labeling of the N-terminus of the diGly remnant. 
Boersema et al. (148) have described a method for performing on-column (C18 
Sep-Pak®) dimethylation of peptide samples. This method was employed with 
small modifications as described in section 14.7 of Experimental Procedures. 
Tissue lysates were prepared from 40 mg of mouse skeletal muscle as described 
in section 14.2 of Experimental Procedures. Proteolysis was done by overnight 
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digestion with trypsin after reduction and alkylation of the cysteines. The tryptic 
peptides were then labeled using the stable isotope dimethyl labeling approach 
described above. The efficiency of labeling as analyzed by mass spectrometry 
was 99.7 and 99.9% for both light and heavy peptides, respectively. 
 
Figure 39. Stable Isotope Dimethyl Labeling. Labeling schemes 
for differential stable isotopic dimethyl labeling. Combination of 
regular formaldehyde and cyanoborohydride generates a mass 
difference of 28Da. Use of deuterated formaldehyde generates a 
mass difference of 32Da. R-remainder of the peptide. 
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3.5. Dimethyl Labeling and diGly Immunoaffinity Purification 
To allow for quantification of ubiquitination of proteins, stable isotope 
dimethyl labeling was incorporated into the diGly immunoaffinity purification 
workflow. Figure 40 A is a diagrammatic representation of the approach. The 
tryptic peptides from mouse skeletal muscle were purified using a Sep-Pak® 
column and on-column labeling was performed during the same purification step. 
This was advantageous as sample clean-up and labeling steps were combined 
and a quenching step was avoided. The labeled tryptic peptides were then 
purified by diGly immunoaffinity purification and analyzed by mass spectrometry. 
The MudPIT-LC/MS analysis failed to detect any diGly peptides although 
numerous unmodified peptides were identified, thus suggesting that 
dimethylation of peptides prior to diGly immunoaffinity purification interfered with 
antibody recognition of the diGly peptides. 
To circumvent this problem, the protocol was modified and the on-column 
labeling was performed after the diGly immunoaffinity purification. The labeled 
peptides were lyophilized and resuspended in buffer for analysis by mass 
spectrometry. Figure 40 B shows the modified approach for dimethyl labeling of 
peptides and diGly immunoaffinity purification in which peptides from the different 
genotypes are mixed after the labeling procedure. 
 
	  Figure 40. Approach for Differential Labeling and diGly Immunoaffinity Purification in Mouse Tissue. 
Approach for A) Dimethyl labeling of tryptic peptides before immunoaffinity purification and B) Dimethyl 
labeling of peptides after immunoaffinity purification. 
 
A 
 
B 
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Figure 41 depicts the MS/MS spectra of heavy and light labeled versions 
of the tryptic peptide, VTIAQGGVLPNIQAVLLPKK, derived from histone H2A. 
The peptide has two labeled sites at the N- and C-termini. There was a mass 
difference of 4 Da between the heavy and the light b ions, which had only one 
labeled site at the N-terminus of the peptide. A mass difference of 8 Da was 
observed between heavy and light y ions because of the presence of two labeled 
sites, the N-terminus of the diGly remnant and the lysine at the C-terminus (Table 
5 and 6). As expected, the peptide ion signals from the heavy and light labeled 
peptides were similar, thus confirming that stable isotope labeling did not alter 
the ubiquitination states of the peptide or interfere with the detection by mass 
spectrometry. 
 
Table 5. Mass Difference between Heavy and Light Labeled b-
ions. Calculated mass difference between light and heavy dimethyl 
labeled peptide derived from histone H2A. (Peptide sequence 
VTIAQGGVLPNIQAVLLPKK). 
 
Seq. No. Light b ion Heavy b ion Mass Difference 
b3 342.29 346.25 3.96 
b4 413.28 417.38 4.10 
b6 598.34 602.46 4.12 
b7 655.44 659.40 3.96 
b9 867.54 871.56 4.02 
b12 1191.84 1195.74 3.90 
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Table 6. Mass Difference between Heavy and Light Labeled y-
ions. Calculated mass difference between light and heavy dimethyl 
labeled peptide derived from histone H2A. (Peptide sequence 
VTIAQGGVLPNIQAVLLPKK). 
 
Seq. No. Light y ion Heavy y ion Mass Difference 
y3 542.35 550.42 8.07 
y5 768.55 776.54 7.99 
y7 938.79 946.69 7.9 
y8 1066.88 1074.77 7.89 
y11 1390.86 1398.87 8.01 
 
 
	   
Figure 41. MS/MS Spectra Showing Dimethyl Labeling. Selected MS/MS spectra of A) heavy and B) light 
labeled tryptic peptide, VTIAQGGVLPNIQAVLLPKK, derived from histone H2A. The y-ion series is shown in 
blue while the b-ion series is shown in red. 
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3.6. Identification of Malin Substrates 
3.6.1. Approach 
Tissue lysates were prepared from skeletal muscle of wild type and 
Epm2b-/- mice. Trypsinolysis of the proteins resulted in the generation of diGly 
remnants on the ubiquitinated peptides, which were immunoaffinity purified with 
anti-diGly antibody. The wild type and Epm2b-/- eluate were differentially labeled 
by stable isotope dimethyl labeling, mixed, lyophilized and analyzed by mass 
spectrometry. In the absence of malin in Epm2b-/- tissue, potential substrates 
should not be ubiquitinated and therefore would lack the diGly remnant (Figure 
42). 
Around 800 mg of frozen mouse skeletal muscle from 6-month-old male 
wild type and Epm2b-/- mice was homogenized as described in section 14.2 of 
Experimental Procedures. The protein yield from tissue of each genotype was 
around 150 mg of protein. Equal amounts of protein were taken for each 
genotype. After reduction and alkylation of cysteines, proteolysis by trypsin was 
done overnight. The diGly peptides generated after trypsinolysis were purified on 
a C18 Sep-Pak® column and immunoaffinity purified using anti-diGly antibody. 
The purified diGly peptides were differentially labeled by dimethylation. The 
peptides from wild type tissue were labeled with heavy and those from Epm2b-/- 
tissue were labeled with light reagents. The differentially labeled peptides were 
mixed and analyzed by mass spectrometry. 
 
	   
Figure 42. Quantitative diGly Proteomics using Dimethyl Labeling in Mouse Skeletal Muscle. Tissue 
lysates from skeletal muscle of wild type and Epm2b-/- mice was digested by trypsin yielding diGly remnant 
on peptides. These peptides were immunoaffinity purified using anti-diGly antibody, differentially labeled by 
dimethylation, mixed and analyzed by mass spectrometry. 
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In our analysis of the data, we observed that tryptic peptide 
NYDIGAALDTIQYSKHPPPL, derived from sequestosome-1 or p62 was present 
in the Epm2b-/- light sample but was absent from the wild type heavy sample. 
Figure 43 shows the heat map showing the relative abundance of diGly peptides 
from different proteins. p62 is a known autophagy substrate and the levels of p62 
are increased upon inhibition of autophagy (44). We observed in section 2.3 of 
Results that autophagy is impaired in MEFs from Epm2b-/- mice. We speculate 
that in the wild type skeletal muscle p62 would be ubiquitinated and degraded, 
however in the Epm2b-/- skeletal muscle, with impairment of autophagy p62 
would accumulate and was therefore detected on mass spectrometry analysis. 
This result corroborates our earlier result that autophagy is impaired in Epm2b-/- 
mice. 
 
3.6.2. Potential Malin Substrates 
As described above, in the absence of malin in the Epm2b-/- tissue, 
potential substrates of malin might not be ubiquitinated and therefore, will lack 
the diGly remnant. Therefore, the absence of the light diGly peptide would 
indicate that the protein is a potential substrate of malin. The proteins identified 
as potential substrates of malin are presented in Tables 7 and 8. Table 7 lists 
malin substrates with at least 2 PSMs and Table 8 contains proteins with only 1 
PSM. In all, 70 proteins were detected that might be substrates of malin. Out of 
these 70 proteins, only 14 proteins had at least 2 PSMs. 
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Table 7. Potential Substrates of Malin E3 Ubiquitin Ligase. 
Proteins with diGly peptides present in wild type but not in Epm2b-/- 
tissue. Peptides with at least 2 PSMs are included. 
 
Accession: The unique accession number for protein in UniProtKB 
Coverage: The percentage of amino acid sequence identified by 
matching tryptic peptides 
# PSMs: The number of peptide spectral matches 
MW: The molecular weight of protein in kilodaltons 
  
Accession Description Coverage #PSMs MW 
A2RTH5 Leucine carboxyl 
methyltransferase 1 
3.01 65 38.2 
Q8R429 Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 1 
46.18 13 109.4 
Q6P4T1 Sorting nexin 19 1.30 6 109.7 
Q9CX83 Armadillo repeat-containing 
X-linked protein 
3.73 4 50.6 
D3YYZ2 C-type lectin domain family 9 46.72 4 14.1 
Q3ULF4 Paraplegin 4 13.45 4 87.01 
E9Q8K5 Titin 28.59 3 3713.7 
Q80U58 Pumilio homolog 2 1.59 3 114.2 
Q02053 Ubiquitin-like modifier-
activating enzyme 1 
5.10 3 117.7 
P05064 Fructose-bisphosphate 
aldolase A 
47.53 3 39.3 
Q14B15 Myomesin 2 38.14 3 164.6 
Q9CS72 Filamin-A-interacting protein 1 1.16 2 137.5 
Q60932 Voltage-dependent anion-
selective channel protein 1 
67.23 2 32.3 
Q9JMH7 Sialidase 3 32.14 2 48 
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Table 8. “One Hit Wonder” Substrates of Malin. Proteins with 
diGly peptides present in wild type but not in Epm2b-/- tissue. 
Peptides with only one PSM are included. 
 
Accession Description Coverage MW 
Q3TYA6 M-phase phosphoprotein 8 1.40 97.4 
E9PWP1 Protein Zfp599 1.82 63.3 
Q91V83 TELO2-interacting protein 1 homolog 2.67 120.7 
Q62073 Mitogen-activated protein kinase 
kinase kinase 7 
2.07 64.2 
Q9D6R2 Isocitrate dehydrogenase subunit alpha 28.14 39.6 
Q3UQ97 Predicted gene EG432838 5.12 27.2 
Q9D5U5 Protein FAM115E 1.53 102.2 
Q91VJ4 Serine/threonine-protein kinase 38 2.58 54.1 
Q6ZQB6 Inositol hexakisphosphate and 
diphosphoinositol-pentakisphosphate 
kinase 2 
1.15 128.3 
Q99KP6 Pre-mRNA-processing factor 19 1.98 55.2 
F6SRT8 Neuron navigator 3 0.73 175.1 
P15975 Inactive ubiquitin carboxyl-terminal 
hydrolase 53 
0.94 119.2 
P0DM40 Fer-1-like protein 5 0.44 235.7 
P09411 Phosphoglycerate kinase 1 59.23 44.5 
Q99KI0 Aconitate hydratase, mitochondrial 34.74 85.4 
J3QMT0 Heterogeneous nuclear 
ribonucleoprotein F 
8.13 23.4 
P18761 Carbonic anhydrase 6 6.31 36.5 
O35098 Dihydropyrimidinase-related protein 4 1.75 61.9 
P62631 Elongation factor 1-alpha 2 25.92 50.4 
P56391 Cytochrome C oxidase subunit 6B1 39.53 10.1 
F8WIU3 Zinc finger protein 618 1.16 95.4 
E9Q6A7 Protein Bptf 0.89 321.4 
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Accession Description Coverage MW 
D3Z007 Interleukin-1 receptor-associated 
kinase 3 
3.48 58.3 
A0AUV4 Sperm motility kinase Y 2.36 57.0 
F6YTC4 Zinc transporter ZIP10 1.54 73.4 
Q5XKE0 Myosin-binding protein C, fast type 44.45 127.3 
Q6P5B0 RRP12-like protein 0.62 143.0 
P21550 Beta-enolase 58.99 47.0 
O54724 Polymerase I and transcript release 
factor 
17.09 43.9 
F6UGV8 Major facilitator superfamily domain-
containing protein 4 
28.36 7.4 
Q9ESB3 Histidine-rich glycoprotein 3.43 59.1 
E9Q2K4 Actin-related protein 2/3 complex 
subunit 5 
6.67 16.1 
O35594 Intraflagellar transport protein 81 
homolog 
1.92 79.2 
O54799 Neuromedin-B receptor  5.90 43.6 
Q9JKX3 Transferrin receptor protein 2  1.25 88.3 
E9QQ10 A-kinase anchor protein 9 0.32 433.9 
Q6PHB0 Interleukin-20 receptor subunit alpha 4.21 61.9 
Q504P4 Heat shock cognate 71 23.44 68.7 
B1ASN7 EF-hand calcium-binding domain-
containing protein 3 
4.18 40.8 
P59240 Nephrocystin-4 0.98 157.2 
Q9R1E6 Ectonucleotide 
pyrophosphatase/phosphodiesterase 
1.86 98.8 
Q3TIV5 Zinc finger CCCH domain-containing 
protein 
3.99 48.3 
D3YV40 Protein kinase C-binding protein 
NELL1 
3.69 42.3 
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Accession: The unique accession number for protein in UniProtKB 
Coverage: The percentage of amino acid sequence identified by 
matching tryptic peptides 
# PSMs: The number of peptide spectral matches 
MW: The molecular weight of protein in kilodaltons 
  
Accession Description Coverage MW 
Q8K224 N-acetyltransferase 10 1.07 115.3 
J3KMJ8 Axonemal dynein light chain domain-
containing protein 1 
0.80 102.2 
Q3TCV3 Gamma-secretase-activating protein 0.93 98.6 
Q07113 Cation-independent mannose-6-
phosphate receptor 
0.52 273.6 
P26262 Plasma kallikrein 1.25 71.3 
F7AIZ1 Protein 1700011I03Rik 3.54 28.3 
E9QPI5 Sister chromatid cohesion protein 
PDS5 homolog A 
0.75 150.1 
Q9D0F9 Phosphoglucomutase 1 44.54 62.0 
Q000896 Alpha-1-antitrypsin 1-3 25.21 44.32 
Q80VM8 PNMA-like protein 1 13.28 48.16 
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Leucine carboxyl methyltransferase 1 or Lcmt1 was present in the wild 
type but not in the malin knockout muscle. Out of all the potential substrates 
identified following diGly immunoaffinity purification and MudPIT-LC/MS analysis, 
Lcmt1 had the highest PSMs at 65. Figure 43 shows the heat map for the 
number of PSMs detected. Figure 44 represents the MS/MS spectrum for the 
tryptic peptide: DLSELEEKLK from Lcmt1. 
Voltage-dependent anion-selective channel protein 1 or Vdac1 is another 
example of a potential malin substrate. Figure 43 shows the heat map for number 
of PSMs for Vdac1. Our analysis showed that two peptides of Vdac1; 
NVNAGGHkLGLGLEFQA and DVFTkGYGFGLIK were ubiquitinated in the wild 
type skeletal muscle but not in the knockout muscle. The MS/MS spectra for the 
two peptides are represented in Figure 45 (NVNAGGHkLGLGLEFQA) and 
Figure 46 (DVFTkGYGFGLIK). 
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Figure 43. Heat Map showing Relative Abundance of diGly 
Peptides. Heat map showing number of peptide spectrum matches 
for differnet proteins identified after diGly immunoaffinity purification 
and MudPIT-LC/MS analysis. 
 
	  
	  Figure 44. MS/MS Spectrum for Lcmt1. MS/MS spectra obtained after diGly immunoaffinity purification 
and MudPIT-LC/MS analysis of tryptic peptide DLSELEEkLk derived from Lcmt1. Lower case lysine in blue 
is ubiquitinated. The fragments for the b-ion series are shown in red while the fragments for the y-ion series 
are shown in blue. 
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  Figure 45. MS/MS Spectrum for Vdac1: 1. MS/MS spectra obtained after diGly immunoaffinity purification 
and MudPIT-LC/MS analysis of tryptic peptide NVNAGGHkLGLGLEFQA derived from Vdac1. Lower case 
lysine in blue is ubiquitinated. The fragments for the b-ion series are shown in red while the fragments for 
the y-ion series are shown in blue. 
	  
130 
	   
Figure 46. MS/MS Spectrum for Vdac1: 2. MS/MS spectra obtained after diGly immunoaffinity purification 
and MudPIT-LC/MS analysis of tryptic peptide DVFTkGYGFGLIK derived from Vdac1. Lower case lysine in 
blue is ubiquitinated. The fragments for the b-ion series are shown in red while the fragments for the y-ion 
series are shown in blue. 
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3.6.3. Bioinformatics Analysis of Potential Malin Substrates 
The proteins that had at least 2 PSMs after diGly immunoaffinity 
purification and MudPIT-LC/MS analysis were subjected to bioinformatics 
analysis by querying the DAVID bioinformatics database. The dataset was 
organized into biofunctional categories and is shown in Figure 47. The results of 
functional annotation clustering by DAVID are presented in Table 9. These 
proteins could be ubiquitinated by malin either as a part of protein degradation 
process or for regulation of activity. The substrates fall into four clusters; 
nucleotide-, metal- and ion-binding, transmembrane proteins and non-membrane 
bound organelles. The nucleotide-binding cluster has the highest enrichment 
score among all the clusters. 
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Figure 47. Biofunctional Categorization of Malin Substrates. 
Using DAVID, biofunctional categorization was performed for 
potential malin substrates identified following diGly immunoaffinity 
purification and MudPIT LC/MS analysis. 
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Table 9. Functional Annotation for Malin Substrates. Using 
DAVID, functional annotation was performed for potential malin 
substrates identified following diGly immunoaffinity purification and 
MudPIT LC/MS analysis. 
 
 
Annotation Cluster 1 p-value 
Enrichment Score: 0.9  
ATP-binding 5.0E-2 
Adenyl ribonucleotide binding 1.1E-1 
Purine Nucleoside binding 1.3E-1 
Ribonucleotide binding 1.8E-1 
Annotation Cluster 2 p-value 
Enrichment Score: 0.78  
Structural molecule activity 5.1E-2 
Non-membrane-bounded organelle 2.9E-1 
Intracellular non-membrane-bounded organelle 2.9E-1 
Annotation Cluster 3 p-value 
Enrichment Score: 0.11  
Metal-binding 5.6E-1 
Metal ion binding 8.7E-1 
Cation binding 8.8E-1 
Ion binding 8.8E-1 
Annotation Cluster 4 p-value 
Enrichment Score: 0.05  
Transmembrane region 7.7E-1 
Integral to membrane 9.0E-1 
Transmembrane 9.1E-1 
Membrane 9.2E-1 
Annotation cluster: A group of terms having similar biological 
meaning due to sharing similar gene members. 
Enrichment score: The overall enrichment score for the group 
based on the EASE scores of each term members; the higher, the 
more enriched. 
p-value: Modified Fisher Exact p-value or the EASE score; the 
smaller, the more enriched. 
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Maere et al. (181) developed an open-source Java tool, the Biological 
Networks Gene Ontology tool or BiNGO, to determine the Gene Ontology (GO) 
terms that are significantly overrepresented in a set of genes. We used BiNGO to 
assess the functional themes present in our set of genes from Table 7. 
Biofunctions with (-log p-values) from this analysis with the GO term is 
represented in Figure 48. The substrates were categorized in nucleotide-, metal- 
or ion-transport, cellular or metabolic processes and muscle function. 
Montojo et al. (182) designed a tool, GeneMANIA, for gene function 
predictions. GeneMANIA is available as a Cytoscape plugin and it identifies the 
most related genes to a query gene set using a guilt-by-association approach. 
Using the GeneMANIA plugin for Cytoscape, we looked for predicted physical 
interactions (Figure 49) and predicted pathways involved  (Figure 50) from our 
set of potential malin substrates. Vdac1 directly interacts with apoptotic gene 
Bax, which interacts with other apoptotic genes, Bid, Bcl2l1 and Moap1. Vdac1 
also interacts indirectly with Aldoa via Vdac1 interaction with Snca. Similarly, 
Dlg4 mediates Vdac1’s interaction with Uba1. GeneMANIA predicted no 
interacting genes for Filip1, Myom2, Armcx1, Lcmt1, Gm5239, Gm3839 and 
Pum2 (Figure 49). GeneMANIA predicted pathways involved multiple pathways 
for groups of genes; for example Vdac1, Ttn and Myom2 were in the pathway 
with predicted genes Trim63 and Tcap (Figure 50). 
 
	   
Figure 48. Gene Ontology.  Using BiNGO, assessment of functional themes was performed for potential 
malin substrates identified following diGly immunoaffinity purification and MudPIT LC/MS analysis. 
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Figure 49. Predicted Physical Interactions by GeneMANIA. 
Using GeneMANIA, physical interactions were predicted for 
potential malin substrates identified following diGly immunoaffinity 
purification and MudPIT LC/MS analysis. Black dots are query 
genes, grey dots are predicted genes, thickness of line represents 
interactions’ score, thicker the line, higher the interaction score. 
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Figure 50. Predicted Pathways by GeneMANIA. Using 
GeneMANIA, pathways involved were predicted for potential malin 
substrates identified following diGly immunoaffinity purification and 
MudPIT LC/MS analysis. Black dots are query genes, grey dots are 
predicted genes, thickness of line represents score for interactions, 
thicker the line, higher the score for involvement in the pathway. 
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DISCUSSION 
Lafora disease was first described by Dr. Gonzalo Lafora and is an 
autosomal recessive neurodegenerative epileptic disorder with onset during early 
adolescence, gradual progression to neurological symptoms and eventually 
death due to cardio-respiratory arrest. Lafora disease is usually a diagnosis of 
exclusion and is confirmed by the presence of characteristic polyglucosan Lafora 
bodies present in many tissues such as skin, neurons, muscle and heart (183). 
So far there is no cure or effective treatment available for Lafora disease. Ninety 
five percent of the patients with Lafora disease have mutations in either of the 
two genes, EPM2A (32) encoding a phosphatase, laforin or EPM2B (81) 
encoding an E3 ubiquitin ligase, malin with clinically indistinguishable symptoms. 
Since the identification of the two genes, Lafora research has been focused on 
defining the physiological functions of laforin and malin and how mutations in 
either gene lead to similar clinical symptoms. Lafora disease is a non-classical 
type of glycogen storage disease and therefore, glycogen metabolism has been 
an obvious area of investigation. 
 
1. Laforin as a Glycogen Phosphatase 
Laforin, a dual specificity phosphatase, contains a carbohydrate-binding 
domain and has been shown to interact more strongly with poorly branched 
polysaccharides such as amylopectin (90,184,185). The first reported substrate 
of laforin was the protein kinase GSK-3 (115,118) that, among other functions, 
regulates glycogen synthase activity. Dephosphorylation of the N-terminal site in 
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GSK-3 would activate the enzyme and in turn decrease glycogen synthase 
activity. In the absence of laforin, glycogen synthase would be activated because 
of the lack of the inhibitory effect of GSK-3. However, other independent studies 
have observed no change in glycogen synthase activity or the phosphorylation 
state of GSK3 in Epm2a-/- mice (9,116,119). Earlier work in our laboratory by 
Tagliabracci et al. demonstrated that laforin functions as a glycogen phosphatase 
in vivo (8,9). Analysis of 9- to 12-month-old Epm2a-/- mice revealed a three-fold 
increase in total glycogen levels and a six-fold increase in glycogen 
phosphorylation (8). Laforin is a glycogen metabolic enzyme that 
dephosphorylates glycogen possibly as part of a “repair” or “damage control” 
mechanism similar to the repair mechanism for DNA (10). Normal glycogen 
contains low amounts of phosphate, which are maintained at structurally 
tolerated levels by laforin. In the absence of laforin in Lafora disease, the cycles 
of glycogen synthesis and degradation proceed relatively normally, but the 
patients gradually start accumulating structurally defective glycogen eventually 
developing polyglucosan Lafora bodies. This also explains the fact that the 
patients are symptom-free with a normal growth curve till early adolescence 
when the cells reach the threshold for glycogen phosphorylation beyond which 
the structurally abnormal glycogen becomes insoluble causing the disease 
pathology. 
Besides functioning as a glycogen phosphatase, laforin could have 
additional functions. Ongoing Lafora research has identified several proteins that 
interact with laforin and most of these proteins are known glycogen-binding 
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proteins. In most cases, laforin has been reported to regulate the activity of these 
interacting proteins with the aid of the E3 ubiquitin ligase malin, (described 
below), which also has been reported to interact with laforin. 
 
2. Malin as an E3 Ubiquitin Ligase 
Defects in malin cause the formation of Lafora bodies and it is interesting 
how mutations in either of the genes lead to the same disease. This could be 
because the two proteins are involved in the same pathway or alternatively, the 
two proteins function independent of each other but converge to the same 
common end point, causing the same phenotype. Malin has been shown to 
biochemically function as an E3 ubiquitin ligase (101). Gentry et al. (101) 
reported that laforin was a substrate of malin. Malin was shown to ubiquitinate 
and degrade laforin via the proteasome. This hypothesis does not explain how in 
the absence of malin, increased levels of laforin could still cause symptoms of 
Lafora disease. Various studies have identified multiple proteins as targets for 
malin, including glycogen synthase (115), debranching enzyme (125), PTG 
(94,117,126,127), laforin (101), neuronatin (128) and AMPK (186). Except for 
AMPK, which is ubiquitinated at K63, all other substrates are modified by K48-
linked polyubiquitination and are targeted to the proteasome for degradation. 
Vilchez et al. (126) proposed that a laforin-malin complex ubiquitinates and 
degrades PTG and in neurons, also glycogen synthase. Worby et al. (127) 
reported that malin degrades PTG in a laforin-dependent manner. Impaired 
degradation of either glycogen synthase or PTG would result in increased 
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glycogen levels by increasing glycogen synthase levels or by increased targeting 
of PP1 leading to dephosphorylation and activation of glycogen synthase. 
Debranching enzyme, AGL, has been shown to be ubiquitinated and degraded 
by malin and in Lafora disease increased AGL levels would lead to abnormal 
branching in glycogen (125). Thus, all these studies focused on the idea that in 
the absence of malin in Lafora disease, there would be elevated levels of the 
substrates that eventually lead to either downstream increase in glycogen levels 
or production of defective glycogen. The studies described so far have been 
performed either in vitro or with overexpression in cultured cells. If the laforin-
malin complex targets these proteins for degradation, one would expect an 
increase in the levels of these proteins in animals lacking malin or laforin. 
However, our analysis of the 3-month-old Epm2b-/- mice (108) revealed no 
differences in the activity of glycogen synthase or protein levels of PTG or AGL in 
skeletal muscle. 
Several studies have also shown that laforin protein level follows glycogen 
accumulation independently of whether Epm2b is deleted or not suggesting that, 
contrary to previous proposals, laforin too is not a malin substrate (108,142,185). 
In the Epm2b-/- mice, we observed increased levels of laforin but only in the 
insoluble fraction, which suggests that malin may prevent the sequestration of 
laforin in the insoluble fraction rather than playing a role in the proteasomal-
dependent degradation of laforin. Turnbull et al. (110) reported that the 
phosphate content of glycogen in Epm2b-/- mice was elevated, but to slightly 
lower levels than Epm2a-/- mice. In Epm2b-/- mice, we showed that laforin was 
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depleted from the soluble fraction (108,110), where it would function to 
dephosphorylate glycogen. This could explain how a loss of function mutation in 
EPM2B would also cause loss of function of laforin and therefore, elevated levels 
of phosphate in the glycogen.	  
 
3. Laforin-malin Complex in Protein Quality Control 
Besides malin’s role in proteasomal degradation of proteins involved in 
glycogen metabolism, the laforin-malin complex has been shown to participate in 
protein quality control to maintain cellular homeostasis. For the most part, these 
studies have been done using an overexpression cell culture model. Mittal et al. 
(187) first reported the formation of aggresomes upon proteasomal inhibition in 
neuronal and non-neuronal cells expressing both laforin and malin. Both proteins 
co-localized to the aggresomes leading to the speculation that laforin and malin 
might be involved in the proteasomal degradation of misfolded proteins and 
laforin might be a novel component of signaling circuits involved with protein 
clearance. Using cellular models for misfolded protein disorders such as 
expanded polyglutamine proteins (Huntingtin disease), polyalanine proteins 
(Ocular-myopathy) and α-synuclein (Parkinson’s disease), the laforin-malin 
complex was shown to form a functional complex with the cellular chaperone, 
Hsp70 and suppressed the cellular toxicity of the aforementioned misfolded 
proteins by promoting their degradation via the ubiquitin-proteasomal and the 
autophago-lysosomal pathway. This was supported by evidence that laforin and 
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malin colocalize with huntingtin aggregates in the neurons of transgenic mice 
model (R6/2) for Huntington disease (129). 
Aguado et al. (121) observed decreased LC3-II and increased p62 in 
human fibroblasts from Lafora disease patients and MEFs from Epm2a-/- mice. 
The impairment of autophagy in the absence of laforin was mTOR-dependent. 
Criado et al. (112) reported that impairment in autophagy in the absence of malin, 
however, was independent of mTOR. Puri et al. (136) speculated that defects in 
the autophagy and endosomal-lysosomal pathways were a cause for Lafora 
disease, but they were unable to report differences in LC3-II in the brain of 
Epm2a-/- mice. These studies argue that defects in protein clearance to be the 
primary cause of the disease phenotype, involving disposal of proteins beyond 
the malin targets involved in glycogen metabolism. 
In an effort to further understand the physiological roles of laforin and 
malin, we analyzed the protein degradation and quality control systems in MEFs 
derived from Epm2a-/-, Epm2b-/- and double Epm2a-/- Epm2b-/- mice. Lack of 
laforin and/or malin impairs autophagy in an mTOR-dependent manner. While 
there was an overall decrease in LC3-II, indicating reduced formation of 
autophagosomes, in all the knockout MEFs, induction of autophagy upon 
starvation or rapamycin treatment was still observed, although to a much lower 
extent than in the wild type cells. This could be because the capacity of the 
knockout MEFs to form new autophagosomes is limited. Criado et al. (112) 
reported that malin regulates autophagy in an mTOR-independent manner, which 
is inconsistent with the conclusion that laforin and malin regulate autophagy as a 
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complex. However, in our studies, both laforin and malin are mTOR-dependent in 
their regulation of autophagy. 
In contrast to previous studies (112,136), we found that in MEFs there was 
proteasomal dysfunction in the absence of either laforin or malin. Deletion of both 
genes in double Epm2a-/- Epm2b-/- MEFs did not cause a further decrease in 
the proteasomal activity. The proteasomal activity was, however, not completely 
absent in the knockout MEFs. Under basal conditions, the levels of ubiquitinated 
proteins were not altered in the knockout MEFs as compared to the wild type 
cells. Upon starvation, ubiquitinated proteins in the wild-type cells were degraded 
either via the proteasome or the lysosome because blocking either of the two 
pathways prevented the degradation of the proteins. However, the starvation-
induced degradation of the ubiquitinated proteins was absent in all the knockout 
MEFs suggesting impairment of the protein clearance pathways. These results, 
therefore, suggest either an overlap in malin and laforin functions or an effect 
secondary to a common phenotype such as generalized cell stress caused by 
abnormal glycogen accumulation (Figure 51). An uncompromised ER stress 
response points towards a secondary effect that becomes enhanced under 
stress. 
 
4. Glycogen Accumulation: Cause or Consequence 
Independent studies by Turnbull et al. (140,188) and Pederson et al. (141) 
have linked the overaccumulation of abnormal glycogen to the causation of 
Lafora disease since genetic reduction of the glycogen levels either by 
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eliminating glycogen synthase or PTG rescues not only Lafora body formation 
but also the neurological symptoms associated with the disease. Recent work by 
Duran et al. (142) showed a reversal of autophagy impairment in Epm2b-/- mice 
with impaired glycogen synthesis. We have observed that decreased glycogen 
accumulation in Epm2b-/- mice restored autophagy markers and proteasomal 
activity in the brain (Unpublished results, A.A. DePaoli-Roach, D.M. Segvich, C. 
J. Contreras, P. Garyali and P.J. Roach). Thus, the defect in protein clearance in 
Lafora disease may be secondary to the accumulation of abnormal glycogen and 
sequestration of cellular proteins in the Lafora bodies. 
 
5. Role of Malin Independent of Laforin 
Interestingly, we found that in Epm2a-/- MEFs levels of GABARAPL1 and 
LAMP1 were similar to wild type but much lower in Epm2b-/- and double Epm2a-
/- Epm2b-/- MEFs, suggesting a function of malin independent of laforin. We 
have shown earlier that Starch-binding domain protein 1 (Stbd1) preferentially 
binds to abnormal and hyperphosphorylated glycogen (33). It has been proposed 
that Stbd1 may participate in the lysosomal trafficking of glycogen by anchoring 
glycogen to intracellular membranes. Stbd1 interacts with GABARAPL1, which 
may function as a novel cargo binding protein that delivers glycogen to 
lysosomes (60). In knockout MEFs, the protein level of Stbd1 is not altered, 
although GABARAPL1, an interacting partner of Stbd1, and LAMP1 are 
decreased in Epm2b-/- and double Epm2a-/- Epm2b-/- MEFs suggesting a 
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possible role of malin in glycogen trafficking to lysosomes and/or lysosome 
biogenesis. 
 
Figure 51. Model of Possible Roles for Laforin and Malin in 
Protein Degradation and Quality Control. Genetic depletion of 
malin and/or laforin resulted in impaired macroautophagy, as 
indexed by LC3 II formation, as well as reduced proteasomal 
degradation of proteins, consistent with laforin and malin either 
acting together or at least in the same pathway. Only loss of malin, 
however, caused decreases in LAMP1 and GABARAPL1, raising 
the possibility of a pathway specific to malin function. The model 
also suggests that effects on autophagy and the 
ubiquitin/proteasomal pathways might be due to generalized cell 
stress secondary to abnormal glycogen metabolism. LF, laforin; 
ML, malin. 
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6. Quantitative diGly Proteomics  
The precise physiological role of malin is still not clear. The targets 
proposed, so far, have not been validated in studies of Epm2b-/- mice. In this 
study, an unbiased quantitative proteomics approach was developed with the 
goal of identifying the physiological substrates of malin. SILAC is a widely used 
proteomics approach to compare two or more conditions or genotypes. Metabolic 
labeling helps obtain the most precise quantification because the different 
samples can be combined before lysis of the cells (189). For this reason, our 
initial attempts were focused on developing a method based on SILAC in primary 
MEFs from wild type and malin knockout mice. Since the cells were not 
immortalized by transformation, they could still represent the cellular picture of 
the corresponding mouse. One of the major difficulties that we faced during these 
experiments was the presence of contaminating serum proteins, mainly albumin. 
The levels of albumin were four orders of magnitude higher than the most 
abundant mouse protein, which considerably interfered with the detection of 
mouse peptides by mass spectrometry (data not shown). Cross-contamination by 
albumin is difficult to avoid because of inherent adherence of albumin to not only 
the cells but also to the culture plates or flasks. A final concentration of 10% 
serum in the medium equates to around 5-6 mg protein/ml from serum (174). 
Extensive washes prior to cell harvesting failed to completely remove albumin to 
levels below detection by mass spectrometry (174). We tried modifying the 
washing techniques by using serum-free medium instead of buffered saline or 
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washing cells in suspension but we were unable to completely eliminate the 
contaminating proteins. 
There are serum-free media commercially available that contain the 
required growth factors and other essential ingredients. We tried sequentially 
adapting the cells to the serum-free medium by gradually changing the ratio of 
full medium: serum-free medium from 100:0 to 0:100. The cells started showing 
altered morphology at 20:80 ratio of full medium: serum-free medium and failed 
to grow at 10:90 ratio. We continued to grow MEFs at low serum concentration of 
2%, which was well tolerated by the cells. There was no change in the 
morphology of the cells, although they grew much more slowly. Serum contains 
factors that bind to the antibiotics added to the medium, thus reducing the 
concentration of antibiotics available. With a 5-fold decrease in the serum 
concentration, the factors would no longer be available at the same ratio to bind 
with the antibiotics. We, therefore, scaled down the concentration of antibiotics to 
prevent cell death because of antibiotics toxicity. 
SILAC ultimately depends on the efficiency of labeling in cells growing in 
heavy or light medium. Incomplete labeling, especially in cells growing in the 
heavy medium, affects the results since it fails to provide the necessary guide as 
to which proteins are from growth in heavy medium. We observed that in our 
primary MEFs efficient labeling was not achieved even after culturing cells in 
heavy medium for 8 weeks. It could be because of issues with amino acid uptake 
specific to primary cells like MEFs. We were unable to resolve these problems. 
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We then established a method for studying the murine skeletal muscle 
ubiquitylome using the quantitative diGly approach. In this study, we identified 
about 244 non-redundant ubiquitinated sites in 142 proteins. We found known 
ubiquitination sites such as lysine 119 in histone H2A (177) and validated our 
approach. Among the 25 most abundant proteins from our study were myosin 
subunits, actin, histones and E3 ubiquitin ligases. There are likely ubiquitinated 
proteins in muscle that we have not been able to identify in our study because of 
inherent stochastic low abundance of certain proteins or loss of the ubiquitin 
moiety during sample preparation despite use of inhibitors. The MS/MS spectra 
were isolated and subjected to detection by high resolution HCD fragmentation in 
addition to CID, thus enabling us to identify the exact ubiquitination site in the 
proteins, but our approach lacks the ability to identity if a protein is mono- or poly-
ubiquitinated. Nine ubiquitination sites were identified in myosin-4, the most 
abundant protein in the mouse muscle ubiquitylome. Five of these ubiquitination 
sites were present only in myosin-4, while four peptides were present in other 
myosin heavy chains as well. So far, there is no experimental evidence in the 
literature for ubiquitination of myosin-4 in mouse muscle. Myosin heavy chains 
could be polyubiquitinated and degraded by the ubiquitin-proteasomal or the 
autophagolysosomal pathway as a part of protein turnover/quality control 
process. The other possibility is that ubiquitination could be a post-translational 
modification for regulation of myosin activity. Since our approach cannot identify 
the type of ubiquitination chain formed, further studies will be required to 
understand the exact role of ubiquitination in myosin and muscle function. 
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To establish a comparative approach to study two different genotypes, we 
optimized immunoaffinity purification using the diGly antibody combined with 
stable isotope dimethyl labeling. The advantage of dimethyl labeling is that it can 
easily be applied to tissues and human samples, which is impossible to perform 
with SILAC. The starting material for the diGly immunoprecipitations or 
immunoprecipitation for other modifications such as phosphorylation is typically 
several milligrams of proteins, which makes the use of labeling with iTRAQ cost-
prohibitive. On the other hand, dimethyl labeling can be performed with 
inexpensive generic reagents without posing financial restrictions to the amount 
of sample to be labeled (148,190). Boersema et al. described the method to 
perform on-column dimethyl labeling of tryptic peptides (148). In this study, we 
further explored and optimized the dimethyl labeling coupled with diGly 
immunoaffinity purification. Our initial approach was to perform chemical labeling 
before immunoprecipitation so that the differentially labeled peptides can be 
immunoprecipitated together, thereby neutralizing the potentially biggest source 
of variation. However, labeling followed by immunoaffinity purification resulted in 
complete failure to detect any diGly peptides. The N-terminus of the diGly 
remnant would be modified by dimethylation and methyl, being a bulky group, 
likely interferes with the interaction of the diGly remnant with the antibody. In our 
final approach, we performed the immunoaffinity purification separately on 
samples derived from the two genotypes followed by the dimethyl labeling. The 
chemical labeling is performed after cell lysis and proteolysis, which makes the 
method more generically applicable to any biological sample including human 
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tissue. Since quantification was done at the peptide rather than protein levels, 
different ubiquitylation events in the same protein can be monitored. 
We used the dimethyl-coupled diGly proteomics approach to search for 
physiological substrates of malin E3 ubiquitin ligase. In the absence of malin in 
Epm2b-/- mice, malin substrates might not be ubiquitinated. After diGly 
immunoaffinity purification and MudPIT-LC/MS analysis, we identified 70 proteins 
which were present in the wild type but not in the Emp2b-/- tissue. Out of these 
proteins, 56 proteins had only 1 peptide spectral match and thus, are not reliable 
as positives in our screen. The remaining proteins had more than 2 peptide 
spectral matches and therefore were more likely to be potential malin substrates. 
Out of these potential malin substrates Leucine carboxyl methyltransferase 1 or 
Lcmt1 had the highest PSM score of 65. In other words, the ubiquitinated tryptic 
peptide of Lcmt1 protein was not detected in skeletal muscle proteome of malin 
knockout mice, but it was detected 65 times in the wild type tissue, which makes 
Lcmt1 very likely to be a substrate of malin. Second in the list was 
sarcoplasmic/endoplasmic reticulum calcium ATPase 1 or Atp2a1 with a PSM 
score of 13. All other potential substrates had a PSM score of less than 10. Since 
the PSM score of Lcmt1 is significantly higher than the other proteins, it makes it 
the most likely substrate of malin that we identified. 
Lcmt1 has been reported to methylate the carboxyl group of the C-
terminal leucine residue of protein phosphatase 2A catalytic subunit, which is 
required for assembly of the holoenzyme containing the B subunit (191,192). 
Lcmt1 is localized to the cytoplasm, Golgi region and the late endosomes (193), 
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is required for normal progression through mitosis and cell survival and is 
essential for embryonic development in mice (194). Recently Sontag et al. 
reported that LCMT1-dependent methylation of PP2A catalytic subunit leads to 
distinct compartmentalization of PP2A and PP2A regulatory enzymes in plasma 
membrane microdomains/rafts of neuroblastoma cells (195). Carboxyl 
methylation of PP2A catalytic subunit is required to regulate the microtubule 
cytoskeleton and tau. Analysis in patients with Alzheimer disease (AD) revealed 
that LCMT1 protein expression and methylation of catalytic subunit of PP2A were 
decreased in AD-affected brain regions (196). Jackson et al. (197) reported an 
increased phosphorylation of Akt T308 upon Lcmt 1 knockdown in 
HEKTERASB56γ cells suggesting that Akt phosphorylation might be regulated 
directly or indirectly by methylation-sensitive PP2A B-subunits. Lcmt 1 
knockdown was also reported to activate p70/p85 S6K and rpS6, so that Lcmt 1-
dependent activation of the S6K pathway might be a consequence of Akt and 
mTOR pathway activation. While further experiments need to be performed to 
validate Lcmt1 as a malin substrate and to understand the role, if any, of Lcmt1 
in Lafora disease, from our analysis by mass spectrometry, Lcmt1 is currently our 
most promising candidate to be a malin substrate. 
In conclusion, we observed that in MEFs from mouse models of Lafora 
disease autophagy is impaired in an mTOR-dependent manner, there is 
impairment of the proteasomal activity while the ER stress response is not 
compromised. We propose that this defect in protein clearance might be 
secondary to generalized cellular stress because of glycogen overaccumulation. 
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Laforin and malin do not always function as a complex and malin may play a role, 
independent of laforin, in lysosomal biogenesis or lysosomal trafficking of 
glycogen. We developed an unbiased comparative quantitative diGly proteomics 
approach to study the mouse muscle ubiquitylome and identified 14 proteins as 
potential malin substrates. We consider Lcmt1 to be a promising candidate 
substrate of the malin E3 ubiquitin ligase. Future experiments will need to focus 
on validation of the potential substrates, Lcmt1 in particular, to understand better 
the precise physiological role of malin in Lafora disease. 
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